var title_f3_32_3584="Urine sediment of a pt with atazanavir crystalluria";
var content_f3_32_3584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph showing urine sediment of a patient with atazanavir crystalluria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment of a patient with atazanavir crystalluria demonstrates a needle shaped crystal with bright field microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Izzedine H, M'rad MB, Bardier A, et al. Atazanavir crystal nephropathy. AIDS 2007; 21:2357. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3584=[""].join("\n");
var outline_f3_32_3584=null;
var title_f3_32_3585="Contents: Lymphoma";
var content_f3_32_3585=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?39/57/40861\">",
"       Hematology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lymphoma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lymphoma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Classification",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/53/21337\">",
"           Classification of the hematopoietic neoplasms",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnosis of non-Hodgkin lymphoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/4/7242\">",
"           AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20042\">",
"           AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7321\">",
"           AIDS-related lymphomas: Primary central nervous system lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30969\">",
"           AIDS-related lymphomas: Primary effusion lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/19/36150\">",
"           Breast lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/51/6970\">",
"           Castleman's disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/53/21337\">",
"           Classification of the hematopoietic neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20358\">",
"           Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/33/21018\">",
"           Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10102\">",
"           Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/45/9945\">",
"           Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/47/25337\">",
"           Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/14/34023\">",
"           Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5256\">",
"           Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/9/19610\">",
"           Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/9/4249\">",
"           Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/1/4119\">",
"           Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38872\">",
"           Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/29/30169\">",
"           Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4618\">",
"           Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35400\">",
"           Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26007\">",
"           Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/20/30023\">",
"           Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/1/9238\">",
"           Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18887\">",
"           Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/40/33416\">",
"           Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/19/35126\">",
"           Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/46/25322\">",
"           Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/61/27610\">",
"           Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/31/9722\">",
"           Clinical presentation, pathologic features, and diagnosis of S������zary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30217\">",
"           Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/56/35720\">",
"           Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/45/24282\">",
"           Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/18/15658\">",
"           Initial evaluation and staging of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13511\">",
"           Intravascular large cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/1/10266\">",
"           Overview of pediatric non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/53/29529\">",
"           Overview of the pathobiology of the non-Hodgkin lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3609\">",
"           Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/19/5433\">",
"           Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/46/2791\">",
"           Pathobiology of Burkitt lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38329\">",
"           Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/41/24215\">",
"           Pathobiology of follicular lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44054\">",
"           Pathobiology of mantle cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15464\">",
"           Primary cutaneous follicle center lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/49/26391\">",
"           Primary cutaneous large B cell lymphoma, leg type",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26776\">",
"           Primary cutaneous marginal zone lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/53/32599\">",
"           Primary lymphoma of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29127\">",
"           Prognosis of diffuse large B cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/17/39194\">",
"           Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4713\">",
"           Staging and prognosis of mycosis fungoides and S������zary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35974\">",
"           Thyroid lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/45/28378\">",
"           Treatment of Langerhans cell histiocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal lymphoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2634\">",
"           Association between Helicobacter pylori infection and gastrointestinal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8714\">",
"           Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3930\">",
"           Management of gastrointestinal lymphomas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/4/7242\">",
"           AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20042\">",
"           AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7321\">",
"           AIDS-related lymphomas: Primary central nervous system lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30969\">",
"           AIDS-related lymphomas: Primary effusion lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38346\">",
"           AIDS-related lymphomas: Treatment of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9750\">",
"           Pulmonary manifestations of HIV-associated lymphoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hodgkin lymphoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34137\">",
"           Cardiotoxicity of radiation therapy for malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33432\">",
"           Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/35/568\">",
"           Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/46/2792\">",
"           Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10711\">",
"           Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13706\">",
"           Effects of cytotoxic agents on gonadal function in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/13/15578\">",
"           Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/49/21274\">",
"           Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29206\">",
"           Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/54/39786\">",
"           Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/0/3079\">",
"           Long-term follow-up of the patient with classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/31/12793\">",
"           Management of classical Hodgkin lymphoma during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30007\">",
"           Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/6/32874\">",
"           Overview of Hodgkin lymphoma in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13512\">",
"           Overview of the treatment of classical Hodgkin lymphoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/38/7784\">",
"           Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/7/38009\">",
"           Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/26/35242\">",
"           Second malignancies after treatment of classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14935\">",
"           Staging and prognosis of Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/23/2426\">",
"           The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/39/3703\">",
"           The role of Epstein-Barr virus in Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11770\">",
"           Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/45/34520\">",
"           Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/17/37145\">",
"           Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27496\">",
"           Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Posttransplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12505\">",
"           Clinical manifestations and diagnosis of acute renal allograft rejection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34170\">",
"           Development of malignancy following solid organ transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/63/31738\">",
"           Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/26/40362\">",
"           Long-term management of adult liver transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/39/28280\">",
"           Malignancy after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/60/12233\">",
"           Noninfectious complications following lung transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23338\">",
"           Treatment and prevention of post-transplant lymphoproliferative disorders",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment of non-Hodgkin lymphoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/19/36150\">",
"           Breast lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/49/12058\">",
"           Hematopoietic cell transplantation in follicular lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/17/18714\">",
"           Initial treatment of advanced stage (III/IV) follicular lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/45/26330\">",
"           Initial treatment of advanced stage diffuse large B cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9865\">",
"           Initial treatment of limited stage (I/II) follicular lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/12/18634\">",
"           Initial treatment of limited stage diffuse large B cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/63/17402\">",
"           Initial treatment of mantle cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/18/33065\">",
"           Initial treatment of peripheral T cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13511\">",
"           Intravascular large cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3609\">",
"           Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/19/5433\">",
"           Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15464\">",
"           Primary cutaneous follicle center lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/49/26391\">",
"           Primary cutaneous large B cell lymphoma, leg type",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26776\">",
"           Primary cutaneous marginal zone lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/53/32599\">",
"           Primary lymphoma of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/17/39194\">",
"           Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33658\">",
"           Therapeutic use and toxicity of high-dose methotrexate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35974\">",
"           Thyroid lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/36/30281\">",
"           Treatment and prognosis of adult T cell leukemia-lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37914\">",
"           Treatment and prognosis of primary central nervous system lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36217\">",
"           Treatment of Burkitt leukemia/lymphoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/35/36410\">",
"           Treatment of advanced stage (IIB to IV) mycosis fungoides and S������zary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17017\">",
"           Treatment of early stage (IA to IIA) mycosis fungoides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/10/12457\">",
"           Treatment of extranodal NK/T cell lymphoma, nasal type",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/41/22169\">",
"           Treatment of marginal zone (MALT) lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/25/33178\">",
"           Treatment of relapsed or refractory diffuse large B cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/10/7338\">",
"           Treatment of relapsed or refractory follicular lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/2/1065\">",
"           Treatment of relapsed or refractory mantle cell lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/8/27785\">",
"           Treatment of relapsed or refractory peripheral T cell lymphoma",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-542E5FD873-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_32_3585=[""].join("\n");
var outline_f3_32_3585=null;
var title_f3_32_3586="Thin endo EFP";
var content_f3_32_3586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasonography of the uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thin endometrium in the early follicular phase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Judith Adams, DMU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3586=[""].join("\n");
var outline_f3_32_3586=null;
var title_f3_32_3587="Fluocinolone (ophthalmic): Pediatric drug information";
var content_f3_32_3587=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/18/29987?source=see_link\">",
"    see \"Fluocinolone (ophthalmic): Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Retisert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10885456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10885584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/18/29987?source=see_link\">",
"      see \"Fluocinolone (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic uveitis: One silicone-encased tablet (0.59 mg) surgically implanted into the posterior segment of the eye is designed to release 0.6 mcg/day, decreasing over 30 days to a steady-state release rate of 0.3-0.4 mcg/day for 30 months. Recurrence of uveitis denotes depletion of tablet, requiring reimplantation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, intravitreal, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retisert&reg;: 0.59 mg (1s) [enclosed in silicone elastomer]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10885585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Handle only by suture tab to avoid damaging the tablet integrity and adversely affecting release characteristics. Maintain strict adherence to aseptic handling of product; do not resterilize.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10885461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Store in original container at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from freezing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10885457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic, noninfectious uveitis affecting the posterior segment of the eye (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluocinolone may be confused with fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8097488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, pain, pyrexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Abnormal sensation, blepharitis, blurred vision, cataract, choroidal detachment, conjunctival edema/chemosis, conjunctival hemorrhage, conjunctival hyperemia, corneal edema, dry eye, eye discharge, eye irritation/inflammation, eyelid edema, eye swelling, glaucoma, hypotony, intraocular pressure increased, eye pain, macular edema, maculopathy, photophobia, photopsia; procedural complications (eg, cataract fragments, implant migration, wound complications);  pruritus, ptosis, retinal hemorrhage, tearing, visual acuity decreased, visual disturbance,  vitreous floaters, vitreous hemorrhage, vitreous opacities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, influenza, nasopharyngitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Secondary infection (bacterial, viral, or fungal)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10885463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinolone or any component; viral, fungal, and mycobacterial ocular infections; hypersensitivity to other corticosteroids",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10885459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10885458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transient decrease in visual acuity of 1-4 weeks duration following implantation may occur. Increased IOP or glaucoma may occur; use with caution in glaucoma patients; routine monitoring of IOP is recommended; patients may require use of medications or other treatments to lower IOP. Prolonged use of ocular corticosteroids may also increase the risk of secondary ocular infections, cataract formation, delayed wound healing, perforation of globe (if thinning of sclera occurs), or optic nerve damage. Unilateral implantation is recommended to minimize risk of postoperative infections in both eyes. Procedural complications with implantation may occur (eg, cataract formation, choroidal detachment, endophthalmitis, hypotony, retinal detachment, vitreous loss, or hemorrhage).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8097492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8097462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted with this product; however, adverse events have been observed with corticosteroids in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10885462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Systemic absorption is negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Releases fluocinolone acetonide at a rate of 0.6 mcg/day, decreasing over 30 days to a steady-state release rate of 0.3-0.4 mcg/day for 30 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Aqueous and vitreous humor",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15988 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3587=[""].join("\n");
var outline_f3_32_3587=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885456\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885584\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100720\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097451\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885585\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885461\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885457\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097406\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097488\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885463\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885459\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885458\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299347\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097492\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097462\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10885462\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15988\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15988|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/18/29987?source=related_link\">",
"      Fluocinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=related_link\">",
"      Fluocinolone (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1220?source=related_link\">",
"      Fluocinolone (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/15/29938?source=related_link\">",
"      Fluocinolone (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=related_link\">",
"      Fluocinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=related_link\">",
"      Fluocinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=related_link\">",
"      Fluocinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_32_3588="Jones fracture nonoperative healing";
var content_f3_32_3588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Nonoperative healing of a Jones fracture in an adolescent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 13-year-old girl sustained a \"Jones\" fracture playing basketball and was treated nonoperatively. A) Initial x-ray shows minimal displacement. B) At 3 months, there is residual lucency, but the patient is asymptomatic. C) At 6 months, consolidation is still delayed but patient remains asymptomatic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3588=[""].join("\n");
var outline_f3_32_3588=null;
var title_f3_32_3589="Amiloride: Patient drug information";
var content_f3_32_3589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amiloride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     see \"Amiloride: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/58/17317?source=see_link\">",
"     see \"Amiloride: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Amiloride&reg;;",
"     </li>",
"     <li>",
"      Midamor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is a strong water pill. Sometimes elements (potassium) in the blood may be raised. The chance is greatest in people with high blood sugar (diabetes), kidney disease, very bad illness, and/or in older adults. Your doctor will follow you closely to change the dose to match your body's needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise potassium stores in the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amiloride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High potassium levels or kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, breast soreness, deeper voice, or more hair growth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10792 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-201.211.0.116-77C6F20116-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3589=[""].join("\n");
var outline_f3_32_3589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133045\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023290\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023292\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023291\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023296\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023297\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023299\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023294\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023295\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023300\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023301\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=related_link\">",
"      Amiloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/58/17317?source=related_link\">",
"      Amiloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_32_3590="Gram stain lesion 1C answer";
var content_f3_32_3590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrotic muscle with clostridial gas gangrene",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin-stained biopsy of muscle (x400) from a patient with clostridial gas gangrene shows extensive necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3590=[""].join("\n");
var outline_f3_32_3590=null;
var title_f3_32_3591="Surgery for prosthetic valve endocarditis";
var content_f3_32_3591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgery for prosthetic valve endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Adolf W Karchmer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3591/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/32/3591/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of a prosthetic heart valve can be difficult to diagnose and manage. Optimal treatment of prosthetic valve endocarditis (PVE) requires:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of the causative microorganism.",
"     </li>",
"     <li>",
"      Selection of a bactericidal antimicrobial regimen of proven efficacy.",
"     </li>",
"     <li>",
"      A clear understanding of the intracardiac pathology and attendant complications of PVE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical intervention in nearly all cases, especially that in which infection has extended beyond the valve to contiguous cardiac tissue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surgical management of prosthetic valve endocarditis will be reviewed here. The antimicrobial treatment of prosthetic valve endocarditis and the role of surgery in native valve endocarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery plays a major role in the effective therapy of many patients with prosthetic valve endocarditis (PVE). Among patients with PVE, 40 to 50 percent are treated surgically, and in another 15 to 20 percent it is likely that surgery is indicated but not performed due to patient refusal or because surgery is contraindicated by complications of PVE or comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Heart failure, persistent fever for 10 or more days despite appropriate antibiotic therapy, systemic embolization, and new onset electrocardiographic conduction abnormalities are associated with high mortality rates in patients with PVE and are clinical indications of invasive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive infection is demonstrated far more predictably by transesophageal echocardiography than by a transthoracic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive infection is common in PVE, especially when infection arises within 12 months of surgery or involves an aortic prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/4\">",
"     4",
"    </a>",
"    ]. For patients with complicated PVE, the survival rates are higher among surgically than medically treated patients, and relapses, rehospitalization for valve surgery, and delayed mortality due to endocarditis are less common among those treated surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/4,5,7-9\">",
"     4,5,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for cardiac surgery in patients with PVE have been developed based upon the intracardiac pathology of PVE and the risk of recrudescent infection on the new prosthesis. The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease included recommendations for surgery in patients with prosthetic and native valve endocarditis (",
"    <a class=\"graphic graphic_table graphicRef54251 \" href=\"UTD.htm?28/12/28875\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the indications for surgical treatment are absolute, while others are relative and require careful risk benefit analysis. Persistent bacteremia despite optimal antimicrobial treatment requires surgical intervention.",
"   </p>",
"   <p>",
"    A multicenter prospective study of 104 patients with PVE examined the influence of medical versus surgical therapy on outcome in order to identify patients for whom surgery may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/11\">",
"     11",
"    </a>",
"    ]. Multivariate analysis identified the following independent predictors of in-hospital mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe heart failure (odds ratio [OR] 5.5; 95% CI, 1.9-16.1)",
"     </li>",
"     <li>",
"      S. aureus infection (OR 6.1; 95% CI, 1.9-19.2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent predictors of long-term mortality (32 month follow-up) included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Comorbidity (risk ratio [RR] 3; 95% CI, 1.4-6.6)",
"     </li>",
"     <li>",
"      Early PVE (&lt;60 days post-surgery, RR 2.1; 95% CI, 1.1-4.3)",
"     </li>",
"     <li>",
"      Severe heart failure (RR 4.2; 95% CI, 2.2-8.0)",
"     </li>",
"     <li>",
"      Staphylococcus infection (RR 2.0; 95% CI, 1.0-4.0)",
"     </li>",
"     <li>",
"      New prosthetic dehiscence (RR 2.4; 95% CI, 1.3-4.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality was not significantly different between surgical and nonsurgical patients overall (17 versus 25 percent), however, in-hospital mortality was reduced by a surgical approach in patients with staphylococcal (27 versus 73 percent) or complicated PVE (18 versus 48 percent).",
"   </p>",
"   <p>",
"    In a study of 556 patients with PVE, in-hospital mortality was significantly associated with age &ge;65 years, healthcare-associated infection, stroke, S. aureus infection, persistent bacteremia, heart failure, and intracardiac abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/2\">",
"     2",
"    </a>",
"    ]. The latter four variables have been considered indications for surgical treatment.",
"   </p>",
"   <p>",
"    An international multi-center prospective study of 355 patients with prosthetic valve endocarditis found the following variables independently associated with surgical therapy: intracardiac abscess, heart failure, younger age, coagulase negative staphylococci, and S. aureus. Unadjusted in-hospital mortality rates in this study were similar for surgical and medical treatment, 25 and 23 percent, respectively. When a propensity analysis was performed to compare surgically treated patients with a population of medically treated patients selected to have similar clinical features, there was a trend toward reduced in-hospital mortality with surgical treatment (OR 0.51; 95% CI 0.23-1.36). A similar trend was noted when all patients with high propensity score for cardiac surgery were examined [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, antibiotic therapy alone is often successful in patients with PVE who have no evidence of heart failure, significant prosthetic valve dysfunction, or invasive infection, and who are infected by less virulent organisms. These patients are characterized by later onset of infection (more than 12 months after prosthesis implantation), and infection by viridans streptococci, HACEK, or enterococci (that can be treated with bactericidal therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Valve dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of PVE in patients who experience moderate to severe heart failure due to prosthesis dysfunction is improved if patients are treated surgically. Few survive beyond six months if treated with antibiotics alone, whereas 44 to 64 percent survive with timely surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/3,5,13,15,16\">",
"     3,5,13,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An unstable hypermobile prosthesis due to dehiscence of anchoring sutures is a surgical emergency, requiring urgent intervention, because the valve is likely to become increasingly unstable with acute severe valve regurgitation.",
"   </p>",
"   <p>",
"    As with NVE, surgical intervention to correct valve dysfunction and severe heart failure is associated with reduced mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/17\">",
"     17",
"    </a>",
"    ]. Surgery must be performed before heart failure becomes intractable. There is no evidence that delaying surgery in this setting improves outcome or reduces the frequency of recurrent endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In fact, the operative mortality of these patients is proportional to the severity of hemodynamic disability at the time of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PVE complicated by perivalvular invasion experience high mortality rates and are rarely curable with medical treatment alone. By contrast, complex reconstructive procedures have been associated with survival rates of 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. Echocardiographic findings are enhanced with transesophageal (versus transthoracic) but can still be limited by \"shadowing\" from prosthetic valve sewing rings. Echocardiographic findings of perivalvular invasion include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Valve dehiscence",
"     </li>",
"     <li>",
"      Perivalvular abscess",
"     </li>",
"     <li>",
"      Aortic aneurysm or pseudoaneurysm",
"     </li>",
"     <li>",
"      Fistula formation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relapse after optimal medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If PVE relapses after appropriate antimicrobial therapy, surgical intervention should usually be performed since relapses often reflect unrecognized perivalvular infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Microorganisms usually requiring surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies suggest that S. aureus PVE is associated with significant mortality, up to 70 percent in patients treated with antibiotics alone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. While mortality outcomes in patients who had surgery in these studies have varied, intracardiac complications in patients with S. aureus PVE are consistently associated with an increased mortality and surgical intervention reduces mortality in this group. In one study, for example, mortality was reduced 20-fold by surgical intervention during antimicrobial therapy (odds ratio [OR] 0.05, 95% CI 0.005-0.42) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/26\">",
"     26",
"    </a>",
"    ]. Although some patients with uncomplicated S. aureus PVE can be treated successfully with antibiotics alone, multiple studies have concluded that PVE caused by S. aureus is most effectively treated by antibiotics and prompt surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/1,5,11,23,24,28\">",
"     1,5,11,23,24,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study, while not finding an improvement in overall mortality with surgical treatment of S. aureus PVE, noted that patients who developed cardiac complications defined as heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intracardiac abscess (a group that would be considered at high risk for endocarditis related death) and underwent early valve replacement had the lowest mortality rate (28.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early surgical intervention is considered by most experts to be a standard element of treatment for fungal PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/29\">",
"     29",
"    </a>",
"    ]. Among 15 patients with fungal PVE treated with antifungal agents and with surgery, 10 (67 percent) survived with an average follow-up of 4.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/30\">",
"     30",
"    </a>",
"    ]. One review of 17 patients suggested that survival rates for Candida PVE were comparable with and without surgery (46 versus 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/31\">",
"     31",
"    </a>",
"    ]. However, only patients with uncomplicated PVE survived in this review, and many remained on long term suppressive oral therapy. Patients who have fungal PVE have significant co-morbidities (such as end-stage renal disease on hemodialysis or immunosuppressed states from chemotherapy or HIV for example). Timing and duration of medical therapy and surgical intervention are frequently complex.",
"   </p>",
"   <p>",
"    Some other pathogens, such as P. aeruginosa and probably multi-resistant enterococci for which there is no synergistic bactericidal regimen, are also less amenable to medical therapy. Surgery is generally advised for PVE caused by these microorganisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of embolic complications is higher in patients with NVE who have vegetations exceeding 10 mm in diameter compared to those with smaller vegetations. Comparable data are not available for patients with PVE. However, the overall rate of embolic complications is similar for patients with PVE and NVE, and emboli decrease rapidly with effective therapy in both [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/32\">",
"     32",
"    </a>",
"    ]. While prevention of emboli that cause highly morbid, irreversible end-organ damage (eg, central nervous system and myocardial infarction) is a laudable goal, it has not been established that surgical intervention achieves this aim in patients with PVE, large vegetations, and no other complications. The risk of emboli in this setting, rather than constituting an indication for surgery, should be weighed with other findings that might benefit from surgical intervention and then factored into the overall management plan. Recurrent emboli despite appropriate antibiotic therapy are an indication for surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ESC recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Society of Cardiology recommends emergent or urgent surgery for PVE when there is severe valve dysfunction or fistula formation and refractory pulmonary edema, cardiogenic shock, or persisting heart failure. Urgent surgery is also advised for uncontrolled infection (abscess, fistula), bacteremia persisting for 7 to 10 days, PVE caused by fungi or multiresistant organisms, and PVE caused by staphylococci or gram-negative bacilli (especially if onset is early after surgery). Similarly, for prevention of emboli after a prior embolus, when there are other indications for surgery and vegetations are large (&gt;10 mm), or perhaps very large vegetations (&gt;15 mm) are present, urgent surgery is recommended. Surgery to prevent emboli based on large vegetations alone is supported by expert opinion only and relatively controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/33\">",
"     33",
"    </a>",
"    ]. Surgery for dehiscent, dysfunctional prosthetic valves in the absence of heart failure can be elective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex reconstruction of the aortic or mitral valve apparatus and the supporting structures is often required to achieve an optimal outcome of PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/22,34-36\">",
"     22,34-36",
"    </a>",
"    ]. In the hands of experienced cardiac surgeons, operative mortality rates for patients with invasive PVE, treated with valve replacement and surgical reconstruction of perivalvular tissue, range from 10 to 30 percent; in contrast the projected mortality would approach 100 percent without surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/8,22,34-37\">",
"     8,22,34-37",
"    </a>",
"    ]. These data suggest that surgical intervention for PVE complicated by extensive invasion and tissue disruption should be performed in centers with extensive experience, when possible. Earlier surgical reintervention in patients with invasive organisms may also significantly limit morbidity by avoiding the need for complex reconstructions (such as root replacement for annular abscess or atrial-ventricular reconstructions for mitral valve prosthetic valve endocarditis).",
"   </p>",
"   <p>",
"    The rate of recrudescent PVE after surgery is six to 15 percent; repeat surgery is required for recurrent PVE or for dysfunction of the newly implanted prosthesis in 18 to 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/4,8,18,22,34,37\">",
"     4,8,18,22,34,37",
"    </a>",
"    ]. While these figures are not insignificant, they are relatively small compared with the anticipated mortality with antibiotic therapy alone. Five-year survival rates ranging from 54 to 82 percent have been reported for patients undergoing surgery for PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/18,22,34,36,38\">",
"     18,22,34,36,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC TREATMENT FOLLOWING SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following valve replacement for active bacterial endocarditis, the Task Force on Infective Endocarditis of the European Society of Cardiology (ESC) recommends another full course (six weeks) of antimicrobial treatment if the intraoperative valve culture is positive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3591/abstract/33\">",
"     33",
"    </a>",
"    ]. We would agree with this approach for culture positive settings and when an acute necrotizing process is found at surgery. If the culture is negative and pathology does not indicate acute necrotizing infection, we would agree with the ESC recommendations that the full treatment course be completed (counting the duration of preoperative antibiotics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTICOAGULANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with prosthetic valve IE, the potential benefit of preventing embolization with anticoagulation must be weighed against the increased risk of intracerebral hemorrhage. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33415?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       \"Patient information: Endocarditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of prosthetic valve endocarditis (PVE) is more difficult than treatment of native valve endocarditis and often requires surgical replacement of the prostheses in addition to antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive infection is common in PVE, especially when infection arises within 12 months of surgery or involves an aortic prosthesis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some of the indications for surgical treatment are absolute, while others are relative and require careful risk benefit analysis (",
"      <a class=\"graphic graphic_table graphicRef54251 \" href=\"UTD.htm?28/12/28875\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcome of PVE in patients who experience moderate to severe heart failure due to prosthesis dysfunction or who have evidence of valve dehiscence, perivalvular abscess, or fistula formation is improved if patients are treated surgically. There is no evidence that delaying surgery in this setting improves outcome or reduces the frequency of recurrent endocarditis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Valve dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is generally advised for PVE caused by S. aureus when accompanied by intracardiac complications, and also for fungi, gram-negative (nonHACEK) microorganisms (particularly P. aeruginosa), and multi-drug resistant enterococci. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Microorganisms usually requiring surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the hands of experienced cardiac surgeons, operative mortality rates for patients with invasive PVE, treated with valve replacement and surgical reconstruction of perivalvular tissue, range from 10 to 30 percent; in contrast the projected mortality approaches 100 percent without surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of recurrent PVE after surgery is 6 to 15 percent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/1\">",
"      Hill EE, Herregods MC, Vanderschueren S, et al. Management of prosthetic valve infective endocarditis. Am J Cardiol 2008; 101:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/2\">",
"      Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/3\">",
"      Karchmer AW, Dismukes WE, Buckley MJ, Austen WG. Late prosthetic valve endocarditis: clinical features influencing therapy. Am J Med 1978; 64:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/4\">",
"      Calderwood SB, Swinski LA, Karchmer AW, et al. Prosthetic valve endocarditis. Analysis of factors affecting outcome of therapy. J Thorac Cardiovasc Surg 1986; 92:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/5\">",
"      Yu VL, Fang GD, Keys TF, et al. Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg 1994; 58:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/6\">",
"      Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; 335:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/7\">",
"      Tornos P, Sanz E, Permanyer-Miralda G, et al. Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest 1992; 101:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/8\">",
"      Saffle JR, Gardner P, Schoenbaum SC, Wild W. Prosthetic valve endocarditis. The case for prompt valve replacement. J Thorac Cardiovasc Surg 1977; 73:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/9\">",
"      Gordon SM, Serkey JM, Longworth DL, et al. Early onset prosthetic valve endocarditis: the Cleveland Clinic experience 1992-1997. Ann Thorac Surg 2000; 69:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/10\">",
"      American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease), Society of Cardiovascular Anesthesiologists, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/11\">",
"      Habib G, Tribouilloy C, Thuny F, et al. Prosthetic valve endocarditis: who needs surgery? A multicentre study of 104 cases. Heart 2005; 91:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/12\">",
"      Wang A, Pappas P, Anstrom KJ, et al. The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J 2005; 150:1086.",
"     </a>",
"    </li>",
"    <li>",
"     Karchmer AW. Infections of Prosthetic Heart Valves. In: Infections Associated with Indwelling Medical Devices, 3rd ed, Waldvogel FA, Bisno AL (Eds), American Society for Microbiology, Washington, DC 2000. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/14\">",
"      Truninger K, Attenhofer Jost CH, Seifert B, et al. Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart 1999; 82:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/15\">",
"      Richardson JV, Karp RB, Kirklin JW, Dismukes WE. Treatment of infective endocarditis: a 10-year comparative analysis. Circulation 1978; 58:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/16\">",
"      Horstkotte D, Bircks W, Loogen F. Infective endocarditis of native and prosthetic valves--the case for prompt surgical intervention? A retrospective analysis of factors affecting survival. Z Kardiol 1986; 75 Suppl 2:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/17\">",
"      Kiefer T, Park L, Tribouilloy C, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA 2011; 306:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/18\">",
"      Baumgartner WA, Miller DC, Reitz BA, et al. Surgical treatment of prosthetic valve endocarditis. Ann Thorac Surg 1983; 35:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/19\">",
"      Boyd AD, Spencer FC, Isom OW, et al. Infective endocarditis. An analysis of 54 surgically treated patients. J Thorac Cardiovasc Surg 1977; 73:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/20\">",
"      Foghsgaard S, Bruun N, Kjaergard H. Outcome of aortic homograft implantation in 24 cases of severe infective endocarditis. Scand J Infect Dis 2008; 40:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/21\">",
"      Reinhartz O, Herrmann M, Redling F, Zerkowski HR. Timing of surgery in patients with acute infective endocarditis. J Cardiovasc Surg (Torino) 1996; 37:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/22\">",
"      Jault F, Gandjbakhch I, Chastre JC, et al. Prosthetic valve endocarditis with ring abscesses. Surgical management and long-term results. J Thorac Cardiovasc Surg 1993; 105:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/23\">",
"      Wolff M, Witchitz S, Chastang C, et al. Prosthetic valve endocarditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision. Chest 1995; 108:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/24\">",
"      R&oslash;der BL, Wandall DA, Espersen F, et al. A study of 47 bacteremic Staphylococcus aureus endocarditis cases: 23 with native valves treated surgically and 24 with prosthetic valves. Scand Cardiovasc J 1997; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/25\">",
"      Kuyvenhoven JP, van Rijk-Zwikker GL, Hermans J, et al. Prosthetic valve endocarditis: analysis of risk factors for mortality. Eur J Cardiothorac Surg 1994; 8:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/26\">",
"      John MD, Hibberd PL, Karchmer AW, et al. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998; 26:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/27\">",
"      Chirouze C, Cabell CH, Fowler VG Jr, et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. Clin Infect Dis 2004; 38:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/28\">",
"      Sett SS, Hudon MP, Jamieson WR, Chow AW. Prosthetic valve endocarditis. Experience with porcine bioprostheses. J Thorac Cardiovasc Surg 1993; 105:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/29\">",
"      Gilbert HM, Peters ED, Lang SJ, Hartman BJ. Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin Infect Dis 1996; 22:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/30\">",
"      Melgar GR, Nasser RM, Gordon SM, et al. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore) 1997; 76:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/31\">",
"      Nguyen MH, Nguyen ML, Yu VL, et al. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis 1996; 22:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/32\">",
"      Steckelberg JM, Murphy JG, Ballard D, et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991; 114:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/33\">",
"      Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/34\">",
"      Lytle BW, Priest BP, Taylor PC, et al. Surgical treatment of prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1996; 111:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/35\">",
"      d'Udekem Y, David TE, Feindel CM, et al. Long-term results of operation for paravalvular abscess. Ann Thorac Surg 1996; 62:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/36\">",
"      David TE. The surgical treatment of patients with prosthetic valve endocarditis. Semin Thorac Cardiovasc Surg 1995; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/37\">",
"      Pansini S, di Summa M, Patane F, et al. Risk of recurrence after reoperation for prosthetic valve endocarditis. J Heart Valve Dis 1997; 6:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3591/abstract/38\">",
"      Delay D, Pellerin M, Carrier M, et al. Immediate and long-term results of valve replacement for native and prosthetic valve endocarditis. Ann Thorac Surg 2000; 70:1219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2132 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-8A237B75EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3591=[""].join("\n");
var outline_f3_32_3591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Valve dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relapse after optimal medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Microorganisms usually requiring surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ESC recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANTIBIOTIC TREATMENT FOLLOWING SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTICOAGULANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/12/28875\" title=\"table 1\">",
"      Surgery prosthetic valve IE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33415?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_32_3592="HLAB5701 carriage frequency";
var content_f3_32_3592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    HLAB5701 carriage frequency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br>",
"      <strong>",
"       * Thailand B*57 carriage:",
"      </strong>",
"      <br>",
"       &nbsp;- Urban Bangkok 3.6 percent",
"       <br>",
"        &nbsp;- Thai Dai Lue (N.E. Thai) &sim;11 percent",
"        <br>",
"         &nbsp;- Southern Thai Muslim 3 percent.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; 8:36. Copyright &copy; 2003 Mediscript Limited.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3592=[""].join("\n");
var outline_f3_32_3592=null;
var title_f3_32_3593="Patent foramen ovale";
var content_f3_32_3593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patent foramen ovale",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3593/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3593/contributors\">",
"     Hidehiko Hara, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3593/contributors\">",
"     Robert S Schwartz, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3593/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3593/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3593/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/32/3593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patent foramen ovale (PFO) is a congenital cardiac lesion that frequently persists into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although most patients with a PFO are asymptomatic, a variety of clinical manifestations may be associated with PFO, most importantly cryptogenic stroke. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Issues related to the prevalence, anatomy, associations with other defects, clinical manifestations and detection of PFO will be reviewed here. Clinical manifestations of atrial septal defects, including PFO, and the indications for and techniques of closure of a PFO are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patent foramen ovale (PFO) was found in 25 to 30 percent of individuals in an autopsy study and in a community-based transesophageal echocardiography (TEE) study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted in the autopsy study of 965 normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Probe-patent PFO was present in 27 percent; the prevalence and size was similar in males and females.",
"     </li>",
"     <li>",
"      The prevalence of PFO declined progressively with age, from 34 percent up to age 30, to 25 percent between ages 30 and 80, to 20 percent over age 80.",
"     </li>",
"     <li>",
"      Among patients who have a PFO, the mean size increased progressively with age, from 3.4 mm up to age 10 to 5.8 mm over age 90. This trend may reflect size selection as larger defects remain patent while smaller defects close spontaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar overall prevalence of PFO (26 percent) was noted in a series of 581 subjects &ge;45 years of age who underwent transesophageal echocardiography as part an evaluation of potential stroke risk factors in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the incidence was stable with increasing age in contrast to the modest decline in the autopsy study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of PFO is higher in patients with cryptogenic stroke, particularly those under age 55 years in whom PFO is more likely to play a causal role. Approximately 40 percent of ischemic strokes in adults under 55 are cryptogenic. In the prospective PFO-ASA study of 581 patients with cryptogenic stroke (mean age 42), 37 percent had a PFO alone and another 9 percent had a PFO with an atrial septal aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/6\">",
"     6",
"    </a>",
"    ]. A similar prevalence of PFO (39 percent) was noted among 250 older patients (mean age 59) with cryptogenic stroke in the Patent Foramen Ovale in Cryptogenic Stroke Study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, the patients with cryptogenic stroke had a significantly higher rate of a large PFO compared to patients with a stroke of known cause (20 versus 9.7 percent). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Cryptogenic stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although most individuals with a PFO are asymptomatic, a PFO can serve as a pathway for venous to arterial transit of emboli (paradoxical emboli) via right-to-left shunting when the pressure in the right atrium exceeds that in the left atrium. A transient right-to-left gradient is sufficient to induce shunting and commonly occurs in patients without net right-to-left shunting (ie, those with no net shunt or a net left-to-right shunt). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H3#H3\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Paradoxical emboli'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A transient right-to-left gradient occurs in normal individuals during early ventricular systole and with Valsalva maneuver (eg, straining to defecate, coughing, lifting or pushing heavy objects). Among 148 patients with a PFO in the community-based series cited above, 57 percent had right-to-left shunting at rest, and 92 percent had right-to-left shunting with straining or coughing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During fetal development, a patent foramen ovale (PFO) is required for oxygenated blood to flow from the right to the left atrium. Starting at week four of pregnancy, the septum primum and septum secundum form and fuse in the following sequence (",
"    <a class=\"graphic graphic_figure graphicRef77749 \" href=\"UTD.htm?2/6/2153\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The septum primum grows from the primordial atrial roof toward the endocardial cushions.",
"     </li>",
"     <li>",
"      The endocardial cushions grow toward each other and then fuse, dividing the atrioventricular canal into right and left sides.",
"     </li>",
"     <li>",
"      The net effect is creation of the foramen primum. As the septum primum continues to grow toward the endocardial cushions, perforations develop in the septum primum. These perforations then fuse, forming the foramen secundum, which allows oxygenated blood to flow from the right to the left atrium. The foramen primum closes.",
"     </li>",
"     <li>",
"      A second membrane, the septum secundum, grows from the right side of the septum primum. The septum secundum eventually overlaps part of the foramen secundum, forming an incomplete septal partition that becomes the foramen ovale. The remaining septum primum forms a flap-like valve over the foramen ovale.",
"     </li>",
"     <li>",
"      Oxygenated blood from the inferior vena cava crosses the PFO, providing oxygenated blood for the systemic circulation. In contrast, most blood from the superior vena cava flows through the tricuspid valve and enters the right ventricle.",
"     </li>",
"     <li>",
"      At birth, either or both of two factors contribute to flap closure against the septum secundum: oxygen filling the alveoli causes the pulmonary arterioles to open, resulting in reductions in right heart pressure and pulmonary vascular resistance; and the increasing amount of blood returning from the pulmonary circulation may raise left atrial pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flap fusion is complete by age two in 70 to 75 percent of children, with the remaining 25 to 30 percent having a PFO. Why PFOs fail to close is not known, but familial and genetic factors may be important. This possibility was suggested in a study that compared 62 patients under age 60 with an ischemic stroke and 62 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/10\">",
"     10",
"    </a>",
"    ]. The prevalence of a PFO in female siblings of patients with a PFO was 77 percent, compared with 25 percent in female siblings of those without a PFO (odds ratio 9.8); there was no such association in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH OTHER DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patent foramen ovale (PFO) is often associated with other cardiac anomalies, including atrial septal aneurysm and Chiari networks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atrial septal aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atrial septal aneurysm (ASA) is defined as redundant and mobile interatrial septal tissue in the region of the fossa ovalis with phasic excursion of at least 10 to 15 mm during the cardiorespiratory cycle. ASAs are frequently associated with PFOs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ASDs. The prevalence and potential clinical significance of ASAs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H6#H6\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Atrial septal aneurysm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link&amp;anchor=H9#H9\">",
"     \"Cryptogenic stroke\", section on 'Atrial septal abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Eustachian valve and Chiari network",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Eustachian valve is located at the junction of the inferior vena cava and the right atrium and is prominent in some individuals. A Chiari network is a more fenestrated mobile structure consisting of a network of threads and fibers in the right atrium that originate from the region of the Eustachian and thebesian valves at the orifice of the inferior vena cava, with attachments to the upper wall of the right atrium or atrial septum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A Chiari network is present in 2 to 3 percent of normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31528?source=see_link&amp;anchor=H17#H17\">",
"     \"Echocardiographic evaluation of the atria and appendages\", section on 'Structure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These structures are not generally thought to be clinically significant. However, a prominent Eustachian valve or Chiari network may maintain an embryonic right atrial flow pattern into adulthood with blood from the inferior vena cava being preferentially directed toward the intraatrial septum. As a result, these structures may favor persistence of a PFO and formation of an ASA or flow through a PFO, indirectly facilitating paradoxical embolism.",
"   </p>",
"   <p>",
"    The association between Chiari network and PFO was illustrated in a review of 1436 consecutive patients referred for TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Chiari network was found in 29 patients (2 percent): 24 (83 percent) had a PFO and 7 (24 percent) had an ASA. Transthoracic echocardiography detected only eight of these networks.",
"     </li>",
"     <li>",
"      A PFO with a large right-to-left shunt occurred with greater frequency in patients with Chiari networks (55 versus 12 percent).",
"     </li>",
"     <li>",
"      Chiari networks were more common in patients undergoing TEE for cryptogenic stroke than in those evaluated for other indications (4.6 versus 0.5 percent). Among the 24 patients with cryptogenic stroke and a Chiari network, 15 had a PFO as the only risk factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of patients undergoing PFO closure, the presence of Eustachian valve or Chiari network was associated with history of recurrent embolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Atrial septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;PFOs are occasionally associated with atrial septal defects (ASDs). In a review of 103 patients referred for transcatheter closure for a presumed paradoxical embolism, PFO alone was present in 81, an ASD alone in 12, and both a PFO and ASD in 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\", section on 'Stroke due to paradoxical embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ebstein's anomaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects of the interatrial septum are present in most patients with Ebstein's anomaly. In a series of 106 patients, 79 percent had either a persistent or previously closed PFO or atrial septal defect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a PFO remain asymptomatic. The most important potential manifestation is ischemic stroke due to a paradoxical embolism. The following is a brief summary, since most of these manifestations are discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cryptogenic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptogenic stroke, which accounts for approximately 20 to 40 percent of ischemic strokes, is defined as a stroke that occurs in the absence of an identified cardioembolic or large vessel source and with a distribution that is not consistent with small vessel disease. Most of these strokes are embolic. There is an increased prevalence of patent foramen ovale (PFO) in patients who have had a cryptogenic stroke; thus, paradoxical embolism via PFO is likely one mechanism for stroke in this population. On the other hand, there is evidence that PFO alone is not associated with an increased risk of recurrent stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link&amp;anchor=H9#H9\">",
"     \"Cryptogenic stroke\", section on 'Atrial septal abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H12#H12\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Prospective and therapeutic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Migraine and vascular headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine and vascular headache may be associated with PFO and right-to-left cardiac shunting. As a result, PFO closure has been evaluated as a treatment for migraine headache. Routine screening for PFO in patients with migraine is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H27#H27\">",
"     \"Preventive treatment of migraine in adults\", section on 'Closure of right-to-left cardiac shunt'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649662#H130649662\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Right-to-left cardiac shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Decompression sickness and air embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompression sickness in scuba divers can result in air embolism through a PFO. The risk is increased with larger PFOs and in patients who travel by air within 12 to 48 hours after diving. PFOs can also permit paradoxical embolization from other causes of air embolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Platypnea-orthodeoxia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platypnea-orthodeoxia syndrome is a rare disorder characterized by both dyspnea (platypnea) and arterial desaturation (orthodeoxia) in the upright position with improvement in the supine position [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In addition to PFO and other interatrial defects, this syndrome has also been described with intrapulmonary shunting and with disorders such as pericardial effusion, constrictive pericarditis, emphysema,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity, pneumonectomy, and cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two components are required [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An interatrial shunt, such as PFO, atrial septal defect, or fenestrated ASA, or intrapulmonary shunting as in the hepatopulmonary syndrome and pulmonary arteriovenous malformations that may occur in patients with cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=see_link\">",
"       \"Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=see_link\">",
"       \"Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A functional component that promotes abnormal shunting when the patient rises from a recumbent to an upright position. This could be mediated by a deformity in the atrial septum (that promotes shunt flow)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the right atrium that increases streaming of blood from the inferior vena cava through the defect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An elevation in right atrial pressure causing right-to-left shunting is usually required, although blood may flow from right to left even when right atrial pressure is normal, as typically occurs with persistent Eustachian valves [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of less common manifestations have been described in patients with a PFO. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28217?source=see_link&amp;anchor=H8#H8\">",
"       \"Coronary heart disease and myocardial infarction in young men and women\", section on 'Paradoxical embolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic embolization, such as renal infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11367?source=see_link\">",
"       \"Diagnosis and treatment of renal infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fat embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=see_link\">",
"       \"Fat embolism syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right atrial tumors causing increased right atrial pressure can promote paradoxical embolization, including tumor embolism [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link&amp;anchor=H4#H4\">",
"       \"Cardiac tumors\", section on 'Right atrial tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Left-sided valve disease in carcinoid syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link\">",
"       \"Carcinoid heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for patent foramen ovale is indicated in patients with cryptogenic stroke or other embolic event as well as in patients with other clinical manifestations of PFO such as platypnea-orthodeoxia syndrome.",
"   </p>",
"   <p>",
"    However, identification of PFO in a patient with an ischemic event does not prove a causal relationship. Since PFO is a common lesion, it may serve as \"innocent bystander\" in some patients with ischemic events. Evaluation of a patient with PFO with an embolic event should include careful assessment of the likelihood that the PFO is causally related to the event including identification of other potential causes of thromboembolism and stroke.",
"   </p>",
"   <p>",
"    Evaluation of sources of venous thromboembolism is also suggested since identification of venous thrombosis provides further support for paradoxical embolism as the mechanism of the embolic event and has treatment implications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H16#H16\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Source of the embolus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ultrasound techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of ultrasound modalities have been used to diagnose a patent foramen ovale (PFO), including transthoracic echocardiography (TTE), transesophageal echocardiography (TEE) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/5,26-30\">",
"     5,26-30",
"    </a>",
"    ], transcranial Doppler (TCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/30-38\">",
"     30-38",
"    </a>",
"    ], and transmitral Doppler (TMD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TTE, TEE, TCD, and TMD, generally in conjunction with injection of agitated saline contrast (a \"bubble study\"), can all detect a right-to-left shunt associated with a PFO. PFO is much more common than other lesions causing intracardiac right-to-left shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, transient right to left shunting is sufficient to cause a positive bubble study and occurs in individuals with PFO with normal intracardiac pressures during early ventricular systole or during Valsalva release. PFO detection can be augmented by cough or releasing a sustained Valsalva maneuver. These maneuvers, which are part of standard echocardiographic (TEE and TTE) testing, open the PFO when the right atrium fills with blood from the abdomen, increasing right-to-left shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. In a TEE study that included 148 patients with a PFO, right-to-left shunting was noted in 57 percent at rest compared to 92 percent with straining or coughing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prevalence and pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     TEE and TTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the ultrasound methods for detection of right-to-left shunts, only TEE enables visualization of the site of the shunt (eg, PFO, ASD or pulmonary arteriovenous malformation) (",
"    <a class=\"graphic graphic_movie graphicRef78654 \" href=\"UTD.htm?12/48/13057\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56656 \" href=\"UTD.htm?32/20/33094\">",
"     movie 2",
"    </a>",
"    ). Echocardiography (TTE or TEE) can also detect other cardiac abnormalities associated with embolic events such as atrial septal aneurysm (ASA) (",
"    <a class=\"graphic graphic_movie graphicRef65962 \" href=\"UTD.htm?15/10/15524\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef50099 \" href=\"UTD.htm?24/40/25231\">",
"     movie 4",
"    </a>",
"    ), intracardiac mass (eg, vegetation, tumor, or thrombus). TEE is generally more sensitive than TTE for identifying potential sources of cardiac embolus including ASA, vegetations, atrial mass or thrombus and thoracic aortic plaque. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TEE enables visualization of the flap of the atrial septum covering the foramen ovale as well as passage of agitated saline contrast through the foramen. Contrast that has passed through a pulmonary arteriovenous malformation may be visualized entering the left atrium via the pulmonary veins. In addition, color Doppler imaging on TEE (and occasionally on TTE) may reveal flow through a PFO at rest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In a small series, PFO detection by contrast and color Doppler TEE correlated well with autopsy findings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of the appearance of agitated saline contrast (bubbles) in the left heart on echocardiography (TTE or TEE) can help distinguish intracardiac shunting (via PFO or ASD) from pulmonary arteriovenous shunting. Early contrast appearance in the left heart (within three beats of contrast appearance in the right heart) suggests intracardiac shunting, while late shunting (after three to five beats) is more consistent with pulmonary arteriovenous shunting. However, the data supporting this timing rule are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/43-45\">",
"     43-45",
"    </a>",
"    ] and exceptions occur [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative efficacy of TTE and TEE has been evaluated in a number of comparative studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, TEE has been found to be more sensitive than TTE for PFO detection, although the reported sensitivity of TEE has varied widely (11 to 85 percent of shunts detected by TEE) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/28-30,47\">",
"       28-30,47",
"      </a>",
"      ]. Variation in the sensitivity of TTE is likely related to variation in image quality.",
"     </li>",
"     <li>",
"      Some later studies have reported that TTE with second harmonic imaging (routinely employed using newer echocardiography systems) had greater sensitivity than TEE for shunt detection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. Potential causes of reduced sensitivity of TEE include ineffective Valsalva maneuver in sedated patients with the TEE probe interfering with glottic closure and reduced right atrial pressures due to fasting and sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/49\">",
"       49",
"      </a>",
"      ]. A limitation of these studies is that a positive TTE or TEE served as the standard for shunt detection, so the rate of false positive results cannot be ascertained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate concern is reduction in sensitivity of echocardiography when images are stored digitally rather than on analog videotape. Although digital acquisition and storage of echocardiographic images are generally recommended by the American Society of Echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/50\">",
"     50",
"    </a>",
"    ], digital data compression by the approved Joint Photographic Experts Group (JPEG) method may result in loss of some visual information. A study comparing digital TTE and analog TTE results found that digital TTE had poor sensitivity for detection of right to left shunts as compared to analog TTE (50, 63 and 39 percent for rest, Valsalva and late shunts, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/47\">",
"     47",
"    </a>",
"    ]. Longer recorded clip length (&ge;13 seconds) was associated with only modest improvement in sensitivity (50, 67, and 46 percent, respectively).",
"   </p>",
"   <p>",
"    Other factors that influence the sensitivity of echocardiography for shunt detection are the site of injection of agitated saline contrast (greater sensitivity with femoral rather than brachial venous injection) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/51\">",
"     51",
"    </a>",
"    ] and the number of bubbles (typically three) required for test positivity.",
"   </p>",
"   <p>",
"    In summary, TEE with contrast at rest, with cough, and following Valsalva is generally considered the most definitive diagnostic test although second harmonic TTE in patients with good acoustic windows may offer equal or greater sensitivity. Among those with cryptogenic stroke or other clinical indication to evaluate for PFO, we suggest starting with TTE, with TEE performed if TTE is negative or nondiagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Transmitral Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preliminary study of 44 patients evaluated the test performance of transmitral Doppler (TMD) echocardiography with agitated saline contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/39\">",
"     39",
"    </a>",
"    ]. The sensitivity and specificity of TMD were 100 and 96 percent when compared with TEE; measures of bubble passage by this technique correlated well with the PFO opening diameter measured with TEE. The role of TMD is uncertain since clinical experience is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Transcranial Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, transcranial Doppler is a potential alternative to TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/30,33-37,39\">",
"     30,33-37,39",
"    </a>",
"    ]. TCD has advantages compared to TEE of being noninvasive and easy to perform at the bedside. On the other hand, TCD can only detect a right-to-left shunt, not the location of the shunt.",
"   </p>",
"   <p>",
"    TCD is performed by placing a probe against the side of the skull just above the zygomatic arch (ie, over the middle cerebral artery). A contrast agent (typically agitated saline) is injected and Doppler ultrasonography is performed at baseline and after a Valsalva maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=see_link\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although early studies suggested that TCD was highly specific but less sensitive than TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], later studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/32,34,35,38\">",
"     32,34,35,38",
"    </a>",
"    ] indicated that these studies are comparable for detection of right-to-left shunts, as concluded in a 2004 report from the American Academy of Neurology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/37\">",
"     37",
"    </a>",
"    ]. However, TEE was considered a better test because it also provides anatomic information about the site and size of the shunt and possible presence of an atrial septal aneurysm and other possible causes of stroke such as aortic atherosclerosis, intracardiac masses, and infective endocarditis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Atrial septal aneurysm'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although intravenous administration of agitated saline contrast for ultrasound detection of shunts has generally been considered safe, case reports suggest that cerebral ischemic events may rarely result from passage of bubbles into the systemic circulation (via an intracardiac shunt or pulmonary arteriovenous malformation) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Although data on techniques to enhance safety are lacking, suggestions include thorough agitation to minimize bubble size, vertical position of the injecting syringe to aid withholding of large bubbles and avoidance of additional contrast injections once a large shunt has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of TEE is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=see_link&amp;anchor=H3#H3\">",
"     \"Transesophageal echocardiography: Indications, complications, and normal views\", section on 'Safety of TEE examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     MDCT and CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary reports suggest that PFO may also be detected by multidetector computed tomography (MDCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/54\">",
"     54",
"    </a>",
"    ] or cardiovascular MR (CMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/55-57\">",
"     55-57",
"    </a>",
"    ], although these methods may be less sensitive than TEE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incidentally detected PFO generally requires no follow-up or treatment.",
"   </p>",
"   <p>",
"    If a PFO is deemed likely to be causally related to an embolic event, therapeutic options for secondary stroke or other embolic event prevention are controversial and include medical therapy with antiplatelet agents or anticoagulation, and surgical or percutaneous closure of the defect. The selection of patients, the possible efficacy of such therapies on patient outcomes, and the lack of benefit and possible harm from closing incidentally discovered PFOs at the time of cardiac surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive treatment for platypnea-orthodeoxia syndrome is closure of the atrial shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/1/12306?source=see_link\">",
"       \"Patient information: Patent foramen ovale (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patent foramen ovale (PFO) occurs in 25 to 30 percent of the general population. The prevalence of PFO is higher in patients with cryptogenic stroke, particularly those under age 55 years in whom PFO is more likely to play a causal role. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most individuals with PFO are asymptomatic although some have clinical manifestations such as cryptogenic stroke, air embolism or platypnea-orthodeoxia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for PFO is indicated in patients with a cerebral ischemic event of uncertain origin or other clinical manifestations of PFO such as platypnea-orthodeoxia.",
"     </li>",
"     <li>",
"      Identification of PFO in a patient with an embolic event does not prove a causal relationship. The evaluation of patients with PFO with an embolic event should include careful assessment of the likelihood that the PFO is causally related to the event including identification of other potential causes of thromboembolism and stroke and of potential sources of venous thromboembolism. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Agitated saline contrast with ultrasound techniques (echocardiography or transcranial Doppler) enables shunt identification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Transesophageal echocardiography (TEE) and transcranial Doppler methods have similar sensitivity and specificity for detection of right-to-left shunts although echocardiography also permits evaluation of cardiac structure and function.",
"     </li>",
"     <li>",
"      On agitated saline contrast echocardiography, appearance of at least three bubbles of contrast in the left heart within three beats after contrast opacification of the right atrium suggests the presence of intracardiac shunt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TEE with contrast at rest, with cough, and following Valsalva is generally considered the most definitive diagnostic test for PFO [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3593/abstract/37\">",
"       37",
"      </a>",
"      ] although second harmonic transthoracic echocardiography (TTE) may offer equal or greater sensitivity in patients with good acoustic windows.",
"     </li>",
"     <li>",
"      Among those with cryptogenic stroke or other clinical indication for evaluation for PFO, we suggest starting with TTE, with TEE performed if TTE is negative or nondiagnostic.",
"     </li>",
"     <li>",
"      Since digital data compression may reduce the sensitivity of agitated saline contrast study, we suggest analog (videotape) recording and review of TTE and TEE contrast studies.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/1\">",
"      Hara H, Virmani R, Ladich E, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol 2005; 46:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/2\">",
"      Wu LA, Malouf JF, Dearani JA, et al. Patent foramen ovale in cryptogenic stroke: current understanding and management options. Arch Intern Med 2004; 164:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/3\">",
"      Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/4\">",
"      Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/5\">",
"      Meissner I, Whisnant JP, Khandheria BK, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc 1999; 74:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/6\">",
"      Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/7\">",
"      Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/8\">",
"      Konstantinides S, Geibel A, Kasper W, et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 1998; 97:1946.",
"     </a>",
"    </li>",
"    <li>",
"     Moore KL. The Developing Human: Clinically Oriented Embryology, 6th ed, Saunders, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/10\">",
"      Arquizan C, Coste J, Touboul PJ, Mas JL. Is patent foramen ovale a family trait? A transcranial Doppler sonographic study. Stroke 2001; 32:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/11\">",
"      Schneider B, Hofmann T, Justen MH, Meinertz T. Chiari's network: normal anatomic variant or risk factor for arterial embolic events? J Am Coll Cardiol 1995; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/12\">",
"      Chiari, H. About network development in the right side of the heart. Beitr Pathol Anat 1897;22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/13\">",
"      Werner JA, Cheitlin MD, Gross BW, et al. Echocardiographic appearance of the Chiari network: differentiation from right-heart pathology. Circulation 1981; 63:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/14\">",
"      Rigatelli G, Dell'avvocata F, Braggion G, et al. Persistent venous valves correlate with increased shunt and multiple preceding cryptogenic embolic events in patients with patent foramen ovale: an intracardiac echocardiographic study. Catheter Cardiovasc Interv 2008; 72:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/15\">",
"      Khositseth A, Cabalka AK, Sweeney JP, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc 2004; 79:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/16\">",
"      Attenhofer Jost CH, Connolly HM, O'Leary PW, et al. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc 2005; 80:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/17\">",
"      Seward JB, Hayes DL, Smith HC, et al. Platypnea-orthodeoxia: clinical profile, diagnostic workup, management, and report of seven cases. Mayo Clin Proc 1984; 59:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/18\">",
"      Cheng TO. Platypnea-orthodeoxia syndrome: etiology, differential diagnosis, and management. Catheter Cardiovasc Interv 1999; 47:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/19\">",
"      Cheng TO. Mechanisms of platypnea-orthodeoxia: what causes water to flow uphill? Circulation 2002; 105:e47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/20\">",
"      Cheng TO. Reversible orthodeoxia. Ann Intern Med 1992; 116:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/21\">",
"      Agostoni P, Gasparini G, Destro G. Acute myocardial infarction probably caused by paradoxical embolus in a pregnant woman. Heart 2004; 90:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/22\">",
"      Diaz Castro O, Bueno H, Nebreda LA. Acute myocardial infarction caused by paradoxical tumorous embolism as a manifestation of hepatocarcinoma. Heart 2004; 90:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/23\">",
"      Carey HB, Boltax R, Dickey KW, Finkelstein FO. Bilateral renal infarction secondary to paradoxical embolism. Am J Kidney Dis 1999; 34:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/24\">",
"      Pell AC, Hughes D, Keating J, et al. Brief report: fulminating fat embolism syndrome caused by paradoxical embolism through a patent foramen ovale. N Engl J Med 1993; 329:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/25\">",
"      Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/26\">",
"      M&uuml;gge A, Daniel WG, Angermann C, et al. Atrial septal aneurysm in adult patients. A multicenter study using transthoracic and transesophageal echocardiography. Circulation 1995; 91:2785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/27\">",
"      Pinto FJ. When and how to diagnose patent foramen ovale. Heart 2005; 91:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/28\">",
"      Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol 1991; 17:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/29\">",
"      Konstantinides S, Kasper W, Geibel A, et al. Detection of left-to-right shunt in atrial septal defect by negative contrast echocardiography: a comparison of transthoracic and transesophageal approach. Am Heart J 1993; 126:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/30\">",
"      Di Tullio M, Sacco RL, Venketasubramanian N, et al. Comparison of diagnostic techniques for the detection of a patent foramen ovale in stroke patients. Stroke 1993; 24:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/31\">",
"      Job FP, Ringelstein EB, Grafen Y, et al. Comparison of transcranial contrast Doppler sonography and transesophageal contrast echocardiography for the detection of patent foramen ovale in young stroke patients. Am J Cardiol 1994; 74:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/32\">",
"      Nemec JJ, Marwick TH, Lorig RJ, et al. Comparison of transcranial Doppler ultrasound and transesophageal contrast echocardiography in the detection of interatrial right-to-left shunts. Am J Cardiol 1991; 68:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/33\">",
"      Teague SM, Sharma MK. Detection of paradoxical cerebral echo contrast embolization by transcranial Doppler ultrasound. Stroke 1991; 22:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/34\">",
"      Blersch WK, Draganski BM, Holmer SR, et al. Transcranial duplex sonography in the detection of patent foramen ovale. Radiology 2002; 225:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/35\">",
"      Droste DW, Lakemeier S, Wichter T, et al. Optimizing the technique of contrast transcranial Doppler ultrasound in the detection of right-to-left shunts. Stroke 2002; 33:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/36\">",
"      Schwarze JJ, Sander D, Kukla C, et al. Methodological parameters influence the detection of right-to-left shunts by contrast transcranial Doppler ultrasonography. Stroke 1999; 30:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/37\">",
"      Sloan MA, Alexandrov AV, Tegeler CH, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/38\">",
"      Droste DW, Schmidt-Rimpler C, Wichter T, et al. Right-to-left-shunts detected by transesophageal echocardiography and transcranial Doppler sonography. Cerebrovasc Dis 2004; 17:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/39\">",
"      Kerr AJ, Buck T, Chia K, et al. Transmitral Doppler: a new transthoracic contrast method for patent foramen ovale detection and quantification. J Am Coll Cardiol 2000; 36:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/40\">",
"      Lynch JJ, Schuchard GH, Gross CM, Wann LS. Prevalence of right-to-left atrial shunting in a healthy population: detection by Valsalva maneuver contrast echocardiography. Am J Cardiol 1984; 53:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/41\">",
"      Schneider B, Zienkiewicz T, Jansen V, et al. Diagnosis of patent foramen ovale by transesophageal echocardiography and correlation with autopsy findings. Am J Cardiol 1996; 77:1202.",
"     </a>",
"    </li>",
"    <li>",
"     Int J Cardiol 2006:109:375.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/43\">",
"      Woods TD, Patel A. A critical review of patent foramen ovale detection using saline contrast echocardiography: when bubbles lie. J Am Soc Echocardiogr 2006; 19:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/44\">",
"      Gazzaniga P, Buscarini E, Leandro G, et al. Contrast echocardiography for pulmonary arteriovenous malformations screening: does any bubble matter? Eur J Echocardiogr 2009; 10:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/45\">",
"      Zukotynski K, Chan RP, Chow CM, et al. Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest 2007; 132:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/46\">",
"      Freeman JA, Woods TD. Use of saline contrast echo timing to distinguish intracardiac and extracardiac shunts: failure of the 3- to 5-beat rule. Echocardiography 2008; 25:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/47\">",
"      Rahmouni HW, Keane MG, Silvestry FE, et al. Failure of digital echocardiography to accurately diagnose intracardiac shunts. Am Heart J 2008; 155:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/48\">",
"      Dani&euml;ls C, Weytjens C, Cosyns B, et al. Second harmonic transthoracic echocardiography: the new reference screening method for the detection of patent foramen ovale. Eur J Echocardiogr 2004; 5:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/49\">",
"      Thanigaraj S, Valika A, Zajarias A, et al. Comparison of transthoracic versus transesophageal echocardiography for detection of right-to-left atrial shunting using agitated saline contrast. Am J Cardiol 2005; 96:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/50\">",
"      Thomas JD, Adams DB, Devries S, et al. Guidelines and recommendations for digital echocardiography. J Am Soc Echocardiogr 2005; 18:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/51\">",
"      Gin KG, Huckell VF, Pollick C. Femoral vein delivery of contrast medium enhances transthoracic echocardiographic detection of patent foramen ovale. J Am Coll Cardiol 1993; 22:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/52\">",
"      Christin F, Bouffard Y, Rossi R, Delafosse B. Paradoxical symptomatic air embolism after saline contrast transesophageal echocardiography. Echocardiography 2007; 24:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/53\">",
"      Romero JR, Frey JL, Schwamm LH, et al. Cerebral ischemic events associated with 'bubble study' for identification of right to left shunts. Stroke 2009; 40:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/54\">",
"      Kim YJ, Hur J, Shim CY, et al. Patent foramen ovale: diagnosis with multidetector CT--comparison with transesophageal echocardiography. Radiology 2009; 250:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/55\">",
"      Mohrs OK, Petersen SE, Erkapic D, et al. Diagnosis of patent foramen ovale using contrast-enhanced dynamic MRI: a pilot study. AJR Am J Roentgenol 2005; 184:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/56\">",
"      Nusser T, H&ouml;her M, Merkle N, et al. Cardiac magnetic resonance imaging and transesophageal echocardiography in patients with transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2006; 48:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/57\">",
"      Mohrs OK, Petersen SE, Erkapic D, et al. Dynamic contrast-enhanced MRI before and after transcatheter occlusion of patent foramen ovale. AJR Am J Roentgenol 2007; 188:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/58\">",
"      Cheng TO. Transcatheter closure of patent foramen ovale: a definitive treatment for platypnea-orthodeoxia. Catheter Cardiovasc Interv 2000; 51:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3593/abstract/59\">",
"      Medina A, de Lezo JS, Caballero E, Ortega JR. Platypnea-orthodeoxia due to aortic elongation. Circulation 2001; 104:741.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1420 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3593=[""].join("\n");
var outline_f3_32_3593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSOCIATION WITH OTHER DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atrial septal aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Eustachian valve and Chiari network",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ebstein's anomaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Migraine and vascular headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Decompression sickness and air embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Platypnea-orthodeoxia syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ultrasound techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - TEE and TTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Transmitral Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Transcranial Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MDCT and CMR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1420\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1420|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2153\" title=\"figure 1\">",
"      Atrial septal embryology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1420|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?12/48/13057\" title=\"movie 1\">",
"      TEE PFO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?32/20/33094\" title=\"movie 2\">",
"      TEE PFO with contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/10/15524\" title=\"movie 3\">",
"      TTE 4Ch IAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/40/25231\" title=\"movie 4\">",
"      TEE IAS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=related_link\">",
"      Contrast echocardiography: Contrast agents, safety, and imaging technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11367?source=related_link\">",
"      Diagnosis and treatment of renal infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31528?source=related_link\">",
"      Echocardiographic evaluation of the atria and appendages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=related_link\">",
"      Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=related_link\">",
"      Management and outcome of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/1/12306?source=related_link\">",
"      Patient information: Patent foramen ovale (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=related_link\">",
"      Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=related_link\">",
"      Transesophageal echocardiography: Indications, complications, and normal views",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=related_link\">",
"      Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_32_3594="Effect of cardiac drugs on platelet function";
var content_f3_32_3594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effect of cardiac drugs on platelet function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3594/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3594/contributors\">",
"     Robert T Eberhardt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3594/contributors\">",
"     Joseph Loscalzo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3594/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3594/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/32/3594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/32/3594/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/32/3594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets participate in the development of coronary heart disease, contributing to atherogenesis as well as coronary thrombosis. The importance of platelets is illustrated by the benefit of antiplatelet therapy with drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and the glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in the treatment of acute and chronic coronary ischemic syndromes and in maintaining long-term patency of intracoronary stents [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to these well-recognized antiplatelet agents, many cardiovascular drugs aimed at nonplatelet mechanisms of ischemia may impair platelet function. There is continued interest in the possibility that the antiplatelet effects of cardiac drugs might influence treatment outcomes.",
"   </p>",
"   <p>",
"    An overview of the impact that cardiovascular agents exhibit on platelet function is provided here. To understand how this might occur, it is useful to begin with a brief discussion of the mechanisms of platelet action and the methods used to assess platelet function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL PLATELET FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primary hemostasis, the platelet response to vascular damage leads to the formation of a hemostatic plug at the site of insult. Platelets then interact with elements of the coagulation cascade to facilitate the incorporation of fibrin into the clot, resulting in clot stabilization. This fibrin-rich clot serves as scaffolding for vascular wall remodeling with the fibrinolytic system ultimately restoring vessel patency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=see_link\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Formation of a hemostatic platelet plug involves platelet adhesion, activation, and aggregation (",
"    <a class=\"graphic graphic_figure graphicRef57152 \" href=\"UTD.htm?22/40/23170\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adhesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both superficial and deep intimal injury disrupt the intact endothelium which normally prevents the adherence of platelets by the production of the antiplatelet agents nitric oxide and prostacyclin. Disruption of the endothelium also exposes collagen. Platelet adhesion is mediated by the binding of platelet receptors to a number of arterial wall receptors, including subendothelial collagen (whose corresponding platelet receptor is glycoprotein",
"    <span class=\"nowrap\">",
"     Ia/IIa),",
"    </span>",
"    von Willebrand factor (Gp",
"    <span class=\"nowrap\">",
"     Ib/IX",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     IIb/IIIa),",
"    </span>",
"    fibrinogen",
"    <span class=\"nowrap\">",
"     (IIb/IIIa),",
"    </span>",
"    and fibronectin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following adhesion, multiple metabolic pathways are stimulated, causing a rise in intracellular calcium through release from intracellular stores and influx from the extracellular space (",
"    <a class=\"graphic graphic_figure graphicRef70151 \" href=\"UTD.htm?11/41/11925\">",
"     figure 2",
"    </a>",
"    ). This increase in cytosolic calcium activates phospholipase A2, leading to the formation of thromboxane A2 (TxA2) (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"UTD.htm?33/29/34269\">",
"     figure 3",
"    </a>",
"    ) and the initiation of actomyosin ATPase activity, resulting in platelet shape change and degranulation of storage granules. The production of TxA2 and the release of other vasoactive substances from storage granules (including adenosine diphosphate and serotonin) leads to the recruitment of adjacent platelets to the growing platelet plug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aggregation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets are linked to one another to form platelet aggregates by the binding of fibrinogen to the receptive form of platelet surface glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa.",
"    </span>",
"    This process is normally opposed by the secretion of prostacyclin from the vascular endothelium.",
"   </p>",
"   <p>",
"    Throughout its lifetime, the platelet is exposed to a diverse array of stimuli that regulate its state of activation and, therefore, its responsiveness to potential vascular insult. These stimuli, both excitatory and inhibitory, act in concert to alter platelet responsiveness through several signal transduction pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Excitatory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major excitatory pathway involves phosphatidylinositol turnover by phospholipase C (PLC) with the generation of the second messengers diacylglycerol, which stimulates protein kinase C, and inositol triphosphate, which leads to increased intracellular calcium release (",
"    <a class=\"graphic graphic_figure graphicRef70144 \" href=\"UTD.htm?19/31/19966\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Strong\" agonists, such as TxA2, thrombin, and platelet activating factor, activate PLC through several families of G proteins.",
"     </li>",
"     <li>",
"      \"Weak\" agonists, such as epinephrine or ADP, activate phospholipase A2 (PLA2), liberating arachidonic acid from membrane phospholipid pools. Arachidonic acid undergoes conversion to TxA2 by the actions of cyclooxygenase and thromboxane synthetase (",
"      <a class=\"graphic graphic_figure graphicRef66146 \" href=\"UTD.htm?33/29/34269\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Erythrocytes can enhance platelet reactivity and the recruitment of additional platelets by promoting the release of intracellular platelet granule components in a thromboxane-independent manner [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/5\">",
"       5",
"      </a>",
"      ]. One study of 82 patients with vascular disease found that, in 60 percent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (200 to 300 mg) was insufficient to block platelet reactivity in the presence of erythrocytes despite the abolition of TxA2 synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inhibitory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major inhibitory signaling pathways employ the cyclic nucleotides, cAMP and cGMP, which antagonize calcium-mediated responses and inhibit PLC and PLA2 activity. Alterations in cAMP levels are mediated by the activity of adenylyl cyclase, which is stimulated by prostacyclin through Gs and inhibited by epinephrine through Gi (",
"    <a class=\"graphic graphic_figure graphicRef67240 \" href=\"UTD.htm?17/30/17902\">",
"     figure 5",
"    </a>",
"    ). Generation of cGMP results from direct binding of nitric oxide to guanylyl cyclase, leading to the activation.",
"   </p>",
"   <p>",
"    Another inhibitory pathway, independent of cGMP, is S-nitrosohemoglobin which is formed by the binding of nitric oxide to thiols of hemoglobin. Upon deoxygenation of hemoglobin in the microcirculation, nitric oxide is released, counteracting platelet activation in small vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/7\">",
"     7",
"    </a>",
"    ]. While this pathway is active in vitro, its relevance in vivo remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF PLATELET FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques are available to measure platelet adhesion, activation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aggregation in vitro and in vivo. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adhesion &mdash; Platelet adhesion can be assessed by quantifying platelet deposition on artificial surfaces in vitro or on vascular wall elements, such as segments of mammalian aortic media, upon exposure to whole blood ex vivo.",
"     </li>",
"     <li>",
"      Platelet activation &mdash; Platelet activation can be assessed directly by measuring the level of second messengers, including calcium or cAMP, produced during activation with an agonist in vitro, and by measurement of the plasma level of products released during degranulation, such as platelet factor-4, beta-thromboglobulin (&szlig;TG), serotonin, or TxA2 metabolites, may provide an indirect assessment of the basal activation state in vivo. In addition, use of whole blood flow cytometry with specific antibodies to measure proteins expressed on the platelet surface during activation, such as P-selectin and GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa,",
"      </span>",
"      permits direct assessment of basal activation in vivo and provides an \"ex vivo\" method to assess agonist-induced activation.",
"     </li>",
"     <li>",
"      Platelet aggregation &mdash; Platelet aggregation can be measured using aggregometry in either platelet-rich plasma or whole blood in response to agonist stimulation in vitro or to sympathoadrenal activation in vivo. Other techniques to assess aggregation include measuring the time for platelet aggregates to occlude a microfilter ex vivo, counting the number of circulating platelet aggregates in vivo, and measuring fibrinogen binding by flow cytometry.",
"     </li>",
"     <li>",
"      Global platelet function &mdash; There are tests that measure global platelet function. Indicators in vivo include the platelet count, platelet size, platelet survival time, and even the bleeding time; however, these tests are insensitive, difficult to interpret,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poorly reproducible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caution must be used when interpreting the results of any of the tests of platelet function because of methodologic problems. As an example, sampling artifact can occur because platelets are easily activated during collection, thereby impairing the ability to measure products of activation or to detect further activation. There are also difficulties applying the analysis of platelet function in systems devoid of the vascular milieu to the functional status of platelets in the circulation.",
"   </p>",
"   <p>",
"    Studies evaluating the impact of cardiovascular drugs on platelet function employed many of these techniques. Those using techniques that most accurately depict the environment of the circulating platelet may provide the most relevant clinical information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMPACT OF CARDIOVASCULAR DRUGS ON PLATELET FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cardiovascular drugs, especially antianginal agents and vasodilators, inhibit platelet function. Antianginal drugs such as nitrates, calcium channel blockers, and beta blockers might be expected to alter platelet function via release of nitric oxide, modification of calcium flux, and alterations in catecholamine balance, respectively.",
"   </p>",
"   <p>",
"    These drugs have been shown to inhibit platelet aggregation in vitro, although usually at high concentrations. Demonstration of in vivo antiplatelet effects at therapeutic concentrations has often been difficult, as different methods of investigation have yielded contradictory results. Despite these difficulties, there remains considerable evidence that impairment of platelet function may contribute to the therapeutic benefit of antianginal agents in the treatment of coronary artery disease. In addition, antithrombotic agents may affect platelet function by altering the interaction between elements of the coagulation cascade and platelets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates and other nitric oxide donors are presumed to exert antiplatelet effects by metabolism to nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/8\">",
"     8",
"    </a>",
"    ]. Nitric oxide then inhibits platelet activation and aggregation in part by increasing the level of cGMP and by inhibiting calcium-mediated responses. Nitric oxide also reduces P-selectin expression and decrease fibrinogen binding to the platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/9\">",
"     9",
"    </a>",
"    ]. Nitric oxide may also modulate prostaglandin biosynthesis, which may exert an inhibitor effect on platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    (NTG) enhances nitric oxide formation, stimulates cGMP accumulation, and inhibits agonist-induced calcium mobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/8\">",
"     8",
"    </a>",
"    ]. It also inhibits agonist-induced platelet aggregation (assessed by aggregometry) in platelet-rich plasma in a dose-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the concentration of NTG used in vitro (80 to 800",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is often much higher than that achieved with therapeutic dosing.",
"   </p>",
"   <p>",
"    Initial clinical studies using in vitro techniques, including agonist-induced aggregation in platelet-rich plasma, failed to confirm an inhibitory effect of NTG administered by infusion at therapeutic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, other investigations utilizing more sensitive methods of assessing platelet function in whole blood have demonstrated a more consistent inhibitory effect of NTG on platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. As an example, inhibition of nitric oxide synthase can lead to platelet activation as manifested by enhanced platelet binding of fibrinogen and increased expression of P-selectin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/17\">",
"     17",
"    </a>",
"    ]. This acute effect can be reversed by sublingual NTG.",
"   </p>",
"   <p>",
"    It is possible that the platelet response to nitrates varies among patient populations. In one study, platelets from patients with stable angina were significantly less responsive to the antiaggregating and cGMP-stimulating effects of nitric oxide donors, including nitrates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , compared to normal controls; this may be due to a reduction in guanylate cyclase sensitivity to nitric oxide",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inactivation of the released nitric oxide by oxygen free radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not universal, other nitrate preparations and other nitric oxide donors also inhibit platelet function. In one report of 40 patients with stable angina,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    decreased platelet reactivity to ADP, reduced TxB2 production, and markedly reduced circulating platelet aggregates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, a randomized, double-blind, placebo-controlled, crossover trial involving 20 patients with stable angina found that isosorbide dinitrate at a lower dose (20 mg twice daily) did not inhibit platelet function as assessed by microfilter occlusion time and &szlig;TG levels immediately after in vivo platelet activation with physical exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of transdermal NTG was assessed in a randomized, double-blind, placebo-controlled trial involving 22 patients with stable angina pectoris [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/20\">",
"     20",
"    </a>",
"    ]. Transdermal NTG decreased agonist-induced aggregation as assessed by whole blood impedance aggregometry and inhibited platelet deposition on porcine aortic media exposed to the patients' venous blood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have been noted with other nitric oxide donors. In one report, an infusion of sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    prevented agonist-induced platelet aggregation across stable coronary lesions following rapid atrial pacing, as measured by whole blood aggregometry [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, S-nitrosoglutathione reduced or prevented induction of P-selectin and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    expression following coronary angioplasty in patients with unstable angina and acute myocardial infarction despite treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is mounting evidence using a variety of techniques supporting an antiplatelet effect of nitrates and other nitric oxide donors. However, the clinical relevance of these antiplatelet actions remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/23\">",
"     23",
"    </a>",
"    ]. At therapeutic dosing, NTG appears to impair platelet adhesion, activation, and aggregation. The clinical relevance of these effects is uncertain. An early review of trials using intravenous nitrates in myocardial infarction suggested a benefit in mortality with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/24\">",
"     24",
"    </a>",
"    ]. However, subsequent large clinical trials, such as GISSI-3 and ISIS-4, failed to demonstrate a mortality benefit of nitrates in patients with an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=see_link\">",
"     \"Nitrates in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, changes in intracellular calcium concentrations play a central role in the platelet response to activation. Calcium channel blockers, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , inhibit platelet aggregation in response to multiple agonists in vitro, as assessed by aggregometry [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/27\">",
"     27",
"    </a>",
"    ]. However, since platelets lack voltage-dependent calcium channels of the L type, which are inhibited by conventional calcium antagonists, the antiplatelet effects must occur by an alternative mechanism. Calcium channel blockers can affect the internal redistribution of calcium in platelets; however, such studies often involve concentrations 10 to 100 times higher than achieved in vivo with therapeutic dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies evaluating the effect of calcium channel blockers on platelet function also suggest that inhibition can occur. This in vivo effect may involve indirect mechanisms, such as neurohumoral activity, endothelial function, or other effects on cellular mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    is the best documented calcium channel blocker with regard to antiplatelet activity. In two double-blind trials, involving patients with hypertension and following acute myocardial infarction, verapamil failed to alter circulating platelet aggregates, inhibit agonist-induced aggregation in platelet-rich plasma or prolong bleeding time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In contrast, an antiplatelet effect has been demonstrated when whole blood techniques are used for measurement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 51 patients with stable angina who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      in the APSIS (Angina Prognosis Study in Stockholm) trial, verapamil (240 mg BID) reduced platelet aggregability both at rest and after exercise although it did not influence agonist-induced aggregation in vitro or &szlig;TG levels [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an uncontrolled study involving 18 patients with stable coronary artery disease,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (240",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for seven days) reduced platelet thrombus formation on porcine aortic media ex vivo and inhibited thrombin-induced platelet aggregation in whole blood ex vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, studies assessing the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    on platelet function using whole blood techniques favor antiplatelet actions, with inhibition of aggregation and adhesion.",
"   </p>",
"   <p>",
"    Studies evaluating the effect of other calcium antagonists on platelet function, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and the dihydropyridines, are equivocal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small uncontrolled studies using in vitro techniques suggest an antiaggregatory effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/33\">",
"       33",
"      </a>",
"      ]. In addition, diltiazem may inhibit platelet activation in patients undergoing percutaneous coronary intervention as manifested by reduced expression of GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      and P-selectin, and by blunting the increase in cytosolic calcium [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dihydropyridines, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"       isradipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      , reduce &szlig;TG and platelet factor-4 levels at rest and after exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/18,28\">",
"       18,28",
"      </a>",
"      ]. In addition, prolonged treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (30 mg daily for eight weeks) decreased platelet aggregation in vitro following exercise-induced activation in patients with worsening angina but not in patients with stable angina or platelet aggregation at rest [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      enhanced P-selectin expression at rest and in response to agonists ADP and thrombin in healthy volunteers as determined with whole blood flow cytometry [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, controlled trials evaluating a possible antiplatelet effect of calcium channel blockers using in vivo methods to assess platelet function are lacking, especially in patients with coronary artery disease. The available data suggest that the different calcium channel blockers exert different effects on platelet function, perhaps due to variable effects on neurohumoral activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      appears to inhibit platelet aggregation",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      may inhibit platelet activation and aggregation, although this effect is less well documented",
"     </li>",
"     <li>",
"      Dihydropyridines may inhibit platelet secretion, although opposing results have been observed with more sensitive whole blood techniques",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical relevance of these effects in the treatment of coronary disease is uncertain. It is possible that the differential effects of these agents on platelet function contribute to the unfavorable outcome in patients with acute coronary syndromes treated with some classes of calcium antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40469?source=see_link\">",
"     \"Calcium channel blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathoadrenal activation activates platelets via adrenergic receptor activation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients with ischemic heart disease usually have more reactive platelets, possibly due to heightened adrenergic stimulation. A beneficial effect of beta blockade in the treatment of ischemic heart disease is well established [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that one of the protective effects of beta blockade may be related to platelet inhibition.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    inhibited agonist-induced platelet aggregation, assessed via aggregometry in platelet-rich plasma, in an in vitro study; however, this occurred only at high drug concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/38\">",
"     38",
"    </a>",
"    ]. At therapeutic concentrations, there is no clear in vitro evidence that beta blockers impair platelet function; to the contrary, proaggregatory effects may been noted, possibly as a consequence of unmasking alpha-2-adrenoceptor-mediated effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of studies evaluating the in vivo effects of beta blockade on platelet function have not produced clear or uniform results. With a few exceptions, the administration of beta blockers to healthy volunteers does not influence platelet function as assessed by various in vitro tests [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/38\">",
"     38",
"    </a>",
"    ]. Limited information is available regarding the effect of beta blockade on platelet function using in vivo techniques. In one report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    had no influence on platelet aggregability in vivo at rest or during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/40\">",
"     40",
"    </a>",
"    ]. In another report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    increased fibrinogen binding in response to agonists ADP and thrombin, suggesting a proaggregatory effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the lack of inhibitory effect of beta blockade on platelet function in healthy volunteers may not apply to patients with coronary disease who may have higher adrenergic tone. However, in vitro and in vivo studies of platelet function after the administration of beta blockers to such patients have also produced inconsistent results. Some have shown an impairment in platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/41-44\">",
"     41-44",
"    </a>",
"    ], while others showed either no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/31,45\">",
"     31,45",
"    </a>",
"    ] or even possible potentiation of platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/38,46,47\">",
"     38,46,47",
"    </a>",
"    ]. A recent study with the highly selective adrenoceptor blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    showed positive correlation between bisoprolol dose and ADP-induced platelet aggregability in patients on dual antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, although beta blockers are beneficial in the treatment of ischemic heart disease, it remains unclear if an effect on platelet function contributes to this benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     ACE inhibitors and angiotensin receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been evidence to suggest that both ACE inhibitors and angiotensin receptor blockers (ARBs) may exert antiplatelet effects. One study demonstrated that the ACE inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    reduced surface expression of the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor and thrombus formation in the early period following a myocardial infarction in 25 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/49\">",
"     49",
"    </a>",
"    ]. Two large studies involving 204 and 303 patients with coronary heart disease or hypertension found that ACE inhibitors reduced platelet aggregation to ADP and collagen by whole blood aggregometry [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study involving 75 subjects with mild to moderate hypertension found an antiplatelet effect of the ARB",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    . Valsartan reduced ADP-induced platelet aggregation, decreased shear-induced platelet activation, and diminished",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    expression and activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These antiaggregatory effects of ACE inhibitors (and perhaps angiotensin receptor blockers) may involve the production of nitric oxide, as nitric oxide synthase inhibition attenuated the beneficial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/53\">",
"     53",
"    </a>",
"    ]. It has been suggested that these effects may override insufficient platelet inhibition by traditional antiplatelet agents in select situations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Amrinone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of inamrinone (formerly known as amrinone), a nonadrenergic inotropic agent, on platelet function has been evaluated in animal model of coronary thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/55\">",
"     55",
"    </a>",
"    ]. Inamrinone inhibited thrombin, ADP, and arginine vasopressin induced calcium mobilization, had modest effects on the expression of the adhesion molecule P-selectin, and inhibited glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor activation. Coronary thrombosis was abolished in the treated animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lipid lowering therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercholesterolemia is associated with enhanced platelet reactivity and platelet-vessel wall interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/56\">",
"     56",
"    </a>",
"    ]. Lipid lowering therapy with a statin decreases platelet aggregation, particularly on eroded vessel walls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/57\">",
"     57",
"    </a>",
"    ] and the production of thromboxane [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In addition, statins appear to inhibit the activity and antigen level of the platelet PAR-1 thrombin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/54\">",
"     54",
"    </a>",
"    ]. A similar antiplatelet effect mediated by PPARs has been shown with fibrates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/61\">",
"     61",
"    </a>",
"    ]. These changes may contribute to the beneficial effect of lipid lowering which cannot be explained by regression of atherosclerosis. Such effects may lead to reduced thrombus formation and enhanced fibrinolysis, thus averting potential acute ischemic events.",
"   </p>",
"   <p>",
"    The clinical relevance of these antiplatelet actions is uncertain. No adverse effects of statins on the antiplatelet action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/62\">",
"     62",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMPACT OF ANTITHROMBOTIC AGENTS ON PLATELET FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interactions of the coagulation cascade, fibrinolytic system, and platelets are critical determinants in the pathogenesis of acute coronary syndromes. Thrombin plays an important role in platelet activation and aggregation as well as coagulation. Thus, antithrombin agents may impair platelet function by preventing thrombin-induced platelet activation. Furthermore, fibrinolysis leads to the generation of prothrombotic factors, which can also lead to platelet aggregation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    exerts its major actions by catalyzing the interaction of antithrombin III and thrombin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .) Heparin might be expected to impair platelet aggregation via a reduction in circulating thrombin. However, in vitro studies have provided contradictory results. Heparin has been reported to reduce, enhance, or have no effect on platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conflicting results on platelet aggregation and activation have also been noted in patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    did not alter ex vivo platelet aggregation to various agonists, including ADP, collagen, and epinephrine in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/65\">",
"     65",
"    </a>",
"    ] while, in another, it increased the expression of P-selectin, activated glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptors, and enhanced platelet aggregation with ADP and the thrombin-receptor agonist peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/66\">",
"     66",
"    </a>",
"    ]. In a report using FACS analysis of whole blood samples, heparin increased GMP 140 surface expression and increased activation by ADP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inhibitory effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    on platelet adhesion has been more consistent. As an example, heparin inhibited platelet adhesion to denuded rabbit aortic segments and reduced platelet deposition following arterial injury after angioplasty in pig carotid arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may have other effects on platelet function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It may induce a form of thrombocytopenia that predisposes to thrombosis (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -associated thrombocytopenia and thrombosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abrupt cessation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may lead to enhanced thrombin generation and reactivation of unstable coronary syndromes. This effect is ameliorated by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , supporting a role of platelets in the process [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Low-molecular-weight-heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low-molecular-weight heparins and heparinoids have variable effects on platelet function, though with less proaggregatory activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/63\">",
"     63",
"    </a>",
"    ]. In one report, low-molecular-weight heparin was more effective than standard heparin in preventing platelet adhesion and the formation of platelet aggregates on damaged vascular surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/68\">",
"     68",
"    </a>",
"    ]. Similarly, the low-molecular weight heparin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    demonstrated greater inhibition of platelet aggregation than unfractionated heparin in 93 patients with unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/71\">",
"     71",
"    </a>",
"    ]. However, another study found that enoxaparin had only minor effects on platelet activation in vivo and ex vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antithrombin agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on whether antithrombins exert antiplatelet effects by directly impairing the platelet agonist action of thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/66,69,72,73\">",
"     66,69,72,73",
"    </a>",
"    ]. In one report, for example, antithrombin agents inhibited thrombin-induced platelet aggregation in vitro but had no effect on aggregation induced by other agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/72\">",
"     72",
"    </a>",
"    ]. In contrast, another study found that the antithrombin agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    , evaluated ex vivo, had no effect on platelet activation or aggregability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite more consistent antiplatelet activity, hirudin conveyed no benefit over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the management of patients with acute myocardial infarction in the TIMI 9B trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H3#H3\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Classification of anticoagulant agents'",
"    </a>",
"    .) The lack of clinical benefit may reflect the fact that activation of platelets by alpha-thrombin is much less effectively exhibited by hirudin than is the procoagulant activity of thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of specific fibrinolytic agents on platelet function, and their interactions with the coagulation pathway, is beyond the scope of this discussion. In general, both proaggregatory and antiplatelet activity may be observed during fibrinolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antiplatelet effects may contribute to hemostatic defects complicating fibrinolytic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/76\">",
"       76",
"      </a>",
"      ]. The reduction in platelet aggregation is greater with streptokinase, less with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"       reteplase",
"      </a>",
"      (mutant recombinant tissue plasminogen activator) and least with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (wild type recombinant tissue plasminogen activator) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"       \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The proaggregatory activity is due both to direct platelet activation by therapeutic concentrations of plasmin, in part by increasing the expression of surface P-selectin, glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor, and",
"      <span class=\"nowrap\">",
"       platelet/endothelial",
"      </span>",
"      cell adhesion molecule-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/78,79\">",
"       78,79",
"      </a>",
"      ] and to indirect platelet activation by plasmin-mediated prothrombinase elaboration and thrombin generation; these factors may contribute to resistance to thrombolysis and reocclusion after successful thrombolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20759?source=see_link\">",
"       \"Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The marked improvement in outcome when thrombolytic therapy is combined with antiplatelet agents suggests that the proaggregatory impact of thrombolytic therapy on platelet function may be clinically important. Support for this comes from one study of 51 patients with an acute infarction who had an evaluation of platelet activation and aggregation before and after treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    or reduced doses of these agents with concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/32/3594/abstract/81\">",
"     81",
"    </a>",
"    ]. Platelet activation and aggregation were enhanced for &ge;24 hours after thrombolytic therapy; abciximab produced &ge;80 percent inhibition of platelet aggregation and evidence of an antiaggregatory effect persisted for 24 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1728852106\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cardiovascular drugs aimed at nonplatelet mechanisms of ischemia may impair platelet function. However, the clinical relevance of most of these antiplatelet actions remains uncertain. The following is a summary of key points in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is mounting evidence supporting an antiplatelet effect of nitrates and other nitric oxide donors. Impairment of platelet adhesion, activation, and aggregation has been observed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nitrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Different calcium channel blockers exert different effects on platelet function, perhaps due to variable effects on neurohumoral activity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of studies evaluating the in vivo effects of beta blockade on platelet function have not produced uniform results. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both angiotensin converting enzyme inhibitors and angiotensin receptor blockers may exert antiplatelet effects (particularly inhibition of aggregation). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'ACE inhibitors and angiotensin receptor blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Statins decrease platelet aggregation and have other effects on platelet function. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lipid lowering therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heparins have variable effect on platelet function. However, their most important effect on platelets is the induction of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -associated thrombocytopenia and thrombosis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both proaggregatory and antiplatelet activity may be observed during fibrinolytic therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Fibrinolytic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/1\">",
"      Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation 1993; 87:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/2\">",
"      Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:2751.",
"     </a>",
"    </li>",
"    <li>",
"     Ware, JA, Coller, BS. Platelet morphology, biochemistry and function. In: Williams' Hematology, Beutler, E, Lichtman, MA, Coller, BS, Kipps, TJ (Eds), McGraw Hill, New York 1994. p.1161.",
"    </li>",
"    <li>",
"     Kroll, MH, Sullivan, R. Mechanisms of platelet activation. In: Thrombosis and Hemorrhage, Loscalzo, J, Schafer, AI (Eds), Blackwell Science, Boston 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/5\">",
"      Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991; 87:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/6\">",
"      Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/7\">",
"      Pawloski JR, Swaminathan RV, Stamler JS. Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. Circulation 1998; 97:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/8\">",
"      Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. J Am Coll Cardiol 1991; 18:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/9\">",
"      Gries A, Bode C, Peter K, et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 1998; 97:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/10\">",
"      Mollace V, Muscoli C, Masini E, et al. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005; 57:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/11\">",
"      Schafer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980; 55:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/12\">",
"      Fitzgerald DJ, Roy L, Robertson RM, FitzGerald GA. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation 1984; 70:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/13\">",
"      Mehta J, Mehta P. Comparative effects of nitroprusside and nitroglycerin on platelet aggregation in patients with heart failure. J Cardiovasc Pharmacol 1980; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/14\">",
"      Diodati J, Th&eacute;roux P, Latour JG, et al. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol 1990; 66:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/15\">",
"      Diodati JG, Cannon RO 3rd, Hussain N, Quyyumi AA. Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am J Cardiol 1995; 75:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/16\">",
"      Chirkov YY, Holmes AS, Chirkova LP, Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 1999; 100:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/17\">",
"      Sch&auml;fer A, Wiesmann F, Neubauer S, et al. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/18\">",
"      Sinzinger H, Virgolini I, O'Grady J, et al. Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease. Thromb Res 1992; 65:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/19\">",
"      Wall&eacute;n NH, Andersson A, Hjemdahl P. Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris. Br J Clin Pharmacol 1994; 38:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/20\">",
"      Lacoste LL, Th&eacute;roux P, Lid&oacute;n RM, et al. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol 1994; 73:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/21\">",
"      Langford EJ, Wainwright RJ, Martin JF. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol 1996; 16:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/22\">",
"      Langford EJ, Brown AS, Wainwright RJ, et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994; 344:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/23\">",
"      Zhou RH, Frishman WH. The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease? Cardiol Rev 2010; 18:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/24\">",
"      Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988; 1:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/25\">",
"      GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/26\">",
"      ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/27\">",
"      Ware JA, Johnson PC, Smith M, Salzman EW. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2. Circ Res 1986; 59:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/28\">",
"      Hjemdahl P, Wall&eacute;n NH. Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997; 18 Suppl A:A36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/29\">",
"      Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens 1994; 8:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/30\">",
"      Kristensen SD, Schmidt EB, Dyerberg J. Verapamil does not alter platelet function in patients with recent myocardial infarction. Thromb Res 1983; 32:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/31\">",
"      Wall&eacute;n NH, Held C, Rehnqvist N, Hjemdahl P. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. Am J Cardiol 1995; 75:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/32\">",
"      L-Lacoste L, Lam JY, Hung J, Waters D. Oral verapamil inhibits platelet thrombus formation in humans. Circulation 1994; 89:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/33\">",
"      Cremer KF, Pieper JA, Joyal M, Mehta J. Effects of diltiazem, dipyridamole, and their combination on hemostasis. Clin Pharmacol Ther 1984; 36:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/34\">",
"      Dai H, Chen J, Tao Q, et al. Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty. Postgrad Med J 2003; 79:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/35\">",
"      Hiroki T, Inoue T, Yoshida T, Arakawa K. Effect of the calcium antagonistic agent nifedipine on platelet aggregation response to exercise in patients with angina pectoris. Arzneimittelforschung 1982; 32:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/36\">",
"      Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/37\">",
"      Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/38\">",
"      Hjemdahl P, Larsson PT, Wall&eacute;n NH. Effects of stress and beta-blockade on platelet function. Circulation 1991; 84:VI44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/39\">",
"      Frishman WH, Furberg CD, Friedewald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984; 310:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/40\">",
"      Larsson, PT, Olsson, G, Hjemdahl, P. Influence of beta-1-blockade on alterations in human platelet aggregability by mental stress and adrenaline infusion (abstract). Eur J Pharmacol 1990; 183:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/41\">",
"      Frishman WH, Christodoulou J, Weksler B, et al. Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. Am Heart J 1978; 95:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/42\">",
"      J&uuml;rgensen HJ, Dalsgaard-Nielsen J, Kj&oslash;ller E, Gormsen J. Effect of long-term beta-blockade with alprenolol on platelet function and fibrinolytic activity in patients with coronary heart disease. Eur J Clin Pharmacol 1981; 20:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/43\">",
"      Winther K, Rein E. Exercise-induced platelet aggregation in angina and its possible prevention by beta 1-selective blockade. Eur Heart J 1990; 11:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/44\">",
"      A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/45\">",
"      Thaulow E, Kjekshus J, Erikssen J. Effect of timolol on platelet aggregation in coronary heart disease. Acta Med Scand Suppl 1981; 651:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/46\">",
"      Gleerup G, Winther K. Differential effects of non-specific beta-blockade and calcium antagonism on blood-clotting mechanisms. Am J Med 1989; 86:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/47\">",
"      Winther K, Knudsen JB, Gormsen J, Jensen J. Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmacol 1986; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/48\">",
"      Ignjatovic VS, Petrovic N, Miloradovic V, et al. The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy. Coron Artery Dis 2010; 21:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/49\">",
"      Zurbano MJ, Anguera I, Heras M, et al. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol 1999; 19:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/50\">",
"      Skowasch D, Lentini S, Andri&eacute; R, et al. [Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study]. Dtsch Med Wochenschr 2001; 126:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/51\">",
"      Bauriedel G, Skowasch D, Schneider M, et al. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Am Heart J 2003; 145:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/52\">",
"      Serebruany VL, Pokov AN, Malinin AI, et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J 2006; 151:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/53\">",
"      Shankar RP, Bhargava VK, Grover A, et al. Involvement of nitric oxide in the antiaggregatory effect of enalapril. Methods Find Exp Clin Pharmacol 2001; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/54\">",
"      Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006; 60:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/55\">",
"      Sill JC, Bertha B, Berger I, et al. Human platelet Ca2+ mobilization, glycoprotein IIb/IIIa activation, and experimental coronary thrombosis in vivo in dogs are all inhibited by the inotropic agent amrinone. Circulation 1997; 96:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/56\">",
"      Badimon JJ, Badimon L, Turitto VT, Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. Arterioscler Thromb 1991; 11:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/57\">",
"      Alfon J, Pueyo Palazon C, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost 1999; 81:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/58\">",
"      Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/59\">",
"      Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/60\">",
"      Notarbartolo A, Dav&igrave; G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/61\">",
"      Ali FY, Armstrong PC, Dhanji AR, et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009; 29:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/62\">",
"      Wenaweser P, Eshtehardi P, Abrecht L, et al. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Thromb Haemost 2010; 104:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/63\">",
"      Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/64\">",
"      Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 1997; 58:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/65\">",
"      Boldt J, M&uuml;ller M, Rothe A, et al. Does continuous heparinization influence platelet function in the intensive care patient? Intensive Care Med 1997; 23:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/66\">",
"      Xiao Z, Th&eacute;roux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/67\">",
"      Klein B, Faridi A, von Tempelhoff GF, et al. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res 2002; 108:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/68\">",
"      Serra A, Esteve J, Reverter JC, et al. Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions. Thromb Res 1997; 87:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/69\">",
"      Heras M, Chesebro JH, Penny WJ, et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/70\">",
"      Th&eacute;roux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/71\">",
"      Malhotra S, Bhargava VK, Grover A, et al. A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial). Int J Clin Pharmacol Ther 2001; 39:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/72\">",
"      Fitzgerald DJ, Fitzgerald GA. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1989; 86:7585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/73\">",
"      Schenk JF, Glusa E, Radziwon P, et al. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time. Haemostasis 1996; 26:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/74\">",
"      Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/75\">",
"      Liu L, Freedman J, Hornstein A, et al. Thrombin binding to platelets and their activation in plasma. Br J Haematol 1994; 88:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/76\">",
"      Kamat SG, Schafer AI. Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis. Coron Artery Dis 1995; 6:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/77\">",
"      Moser M, Nordt T, Peter K, et al. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. Circulation 1999; 100:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/78\">",
"      Kawano K, Aoki I, Aoki N, et al. Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression. Am Heart J 1998; 135:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/79\">",
"      Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/80\">",
"      Leopold JA, Loscalzo J. Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Coron Artery Dis 1995; 6:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/32/3594/abstract/81\">",
"      Coulter SA, Cannon CP, Ault KA, et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation 2000; 101:2690.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1512 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3594=[""].join("\n");
var outline_f3_32_3594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1728852106\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL PLATELET FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adhesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aggregation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Excitatory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inhibitory pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ASSESSMENT OF PLATELET FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMPACT OF CARDIOVASCULAR DRUGS ON PLATELET FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nitrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACE inhibitors and angiotensin receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Amrinone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lipid lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMPACT OF ANTITHROMBOTIC AGENTS ON PLATELET FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Low-molecular-weight-heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antithrombin agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1728852106\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1512\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1512|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/40/23170\" title=\"figure 1\">",
"      Pathways of platelet activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/41/11925\" title=\"figure 2\">",
"      Mechanism platelet activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34269\" title=\"figure 3\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/31/19966\" title=\"figure 4\">",
"      Phosphatidylinositol turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/30/17902\" title=\"figure 5\">",
"      Adenylyl cyclase",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40469?source=related_link\">",
"      Calcium channel blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=related_link\">",
"      Nitrates in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20759?source=related_link\">",
"      Predictors of coronary artery reocclusion following fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_32_3595="Classification of liver test abnormalities";
var content_f3_32_3595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of liver test abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hepatitis (hepatocellular)",
"       </td>",
"       <td>",
"        ALT &ge;3 x ULN",
"       </td>",
"       <td>",
"        R &ge;5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis",
"       </td>",
"       <td>",
"        ALP &ge;2 x ULN",
"       </td>",
"       <td>",
"        R &le;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed",
"       </td>",
"       <td>",
"        <p>",
"         ALT &ge;3 x ULN",
"        </p>",
"        <p>",
"         ALP &ge;2 x ULN",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         R &gt;2 to &lt;5",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase; ALP: alkaline phosphatase; ULN: upper limit normal; R: ALT/ULN divided by ALP/ULN.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3595=[""].join("\n");
var outline_f3_32_3595=null;
var title_f3_32_3596="Spectrum of activity of the tetracyclines";
var content_f3_32_3596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of activity of the tetracyclines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pathogens/syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsial infections (doxycycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydial infections (doxycycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traveler's diarrhea (doxycycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early Lyme disease (doxycycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroquine-resistant malaria (doxycycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acne",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amebiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actinomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Borrelia recurrentis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Legionnaire's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptospirosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium marinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melioidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningococcal prophylaxis (minocycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRSA (minocycline or tigecycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocardiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcus aureus (minocycline or tigecycline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tularemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vibrio vulnificus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VRE (susceptible strains)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipple's disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3596=[""].join("\n");
var outline_f3_32_3596=null;
var title_f3_32_3597="Salicylate poisoning in adults - Rapid overview";
var content_f3_32_3597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Salicylate poisoning in adults: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical and laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common: tachypnea, tinnitus, nausea, vomiting, acid-base abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe cases: hyperthermia, altered mental status, pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma salicylate concentration, arterial blood gas (ABG), basic electrolytes, BUN and creatinine, chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeat salicylate concentration every two hours until it is declining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeat ABG every two hours until acid-base status stable or improving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Avoid intubation if at all possible",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer supplemental oxygen as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume resuscitate unless cerebral or pulmonary edema is present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer multiple doses of activated charcoal (first dose: 1 g/kg orally up to 50 g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer supplemental glucose in patients with altered mental status, even if serum glucose concentration is normal: IV dextrose 50 g as 100 mL of 50 percent dextrose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Alkalinize with sodium bicarbonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bolus therapy: sodium bicarbonate, 1 to 2 mEq/kg (maximum 100 mEq) IV push over 3 to 5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maintenance therapy: 100 to 150 mEq sodium bicarbonate in 1 L of D5W, run at 250 mL/hour in adults OR run at 1.5 to 2 times maintenance in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Correct hypokalemia, hypocalcemia and other electrolyte abnormalities. IV sodium bicarbonate is NOT compatible with calcium salts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alkalemia (arterial pH up to 7.55) is NOT a contraindication to sodium bicarbonate therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        DO NOT USE ACETAZOLAMIDE TO ALKALINIZE THE URINE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Alert nephrology team early in the patient's clinical course; indications for hemodialysis include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Profoundly altered mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary or cerebral edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal insufficiency that interferes with salicylate excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluid overload that prevents the administration of sodium bicarbonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        A plasma salicylate concentration &gt;100 mg/dL (7.2 mmol/L) in acute ingestion OR &gt;60 mg/dL (4.3 mmol/L) in chronic ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clinical deterioration despite aggressive and appropriate supportive care",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3597=[""].join("\n");
var outline_f3_32_3597=null;
var title_f3_32_3598="Puncture technique";
var content_f3_32_3598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Puncture technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3598=[""].join("\n");
var outline_f3_32_3598=null;
var title_f3_32_3599="FOLFOXIRI";
var content_f3_32_3599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FOLFOXIRI chemotherapy for metastatic colorectal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        165 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 500 mL 5 percent dextrose in water (D5W)",
"        <sup>",
"         &Delta;",
"        </sup>",
"        to a final concentration of 0.12 to 2.8 mg/mL and administer over 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL D5W and administer over two hours after irinotecan. Administer concurrently with leucovorin in separate bags via y-line connection",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         LEVOleucovorin",
"        </strong>",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL D5W and administer over two hours, concurrent with oxaliplatin.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400 to 3200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL D5W and administer over 48 hours, after leucovorin. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL). The original protocol used 3200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , but many US oncologists use a lower starting dose (2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ) and escalate as tolerated to reach a final dose of 3200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin and fluorouracil are irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Routine primary prophylaxis with G-CSF is not warranted (estimated risk of febrile neutropenia 5 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). However, given the high rate of grade 3 or 4 neutropenia (approximately 50 percent), primary prophylaxis may be considered for high-risk patients. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of oxaliplatin and irinotecan may be needed for patients with severe renal insufficiency",
"        <sup>",
"         [3,4]",
"        </sup>",
"        . A lower starting dose of irinotecan and FU may be needed for patients with hepatic impairment",
"        <sup>",
"         [4,5]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Irinotecan is associated with early and late diarrhea, both of which may be severe",
"        <sup>",
"         [4]",
"        </sup>",
"        . Patients must be instructed in the early use of loperamide for late diarrhea. Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) should provided as needed. For patients who develop abdominal cramping and/or diarrhea within 24 hours of receiving irinotecan, adminster atropine (0.3 to 0.6 mg IV) and premedicate with atropine for later cycles. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        The specific dose alteration parameters for the FOLFOXIRI regimen in colorectal cancer patients were not published in the original phase III trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . The following suggestions are based upon dose reductions used in a trial using a comparable regimen (FOLFIRINOX) for advanced pancreatic cancer",
"        <sup>",
"         [6]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Do not retreat unless granulocyte count &ge;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is &ge;75,000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neutropenia:",
"        </strong>",
"        If day 1 treatment delayed for granulocytes &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or febrile neutropenia or grade 4 neutropenia &gt;7 days, reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and reduce the continuous infusion FU to 75 percent of original doses. For second occurrence, reduce oxaliplatin dose to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the dose of infusional FU an additional 25 percent. If non-recovery after two weeks, delay or third occurrence of granulocytes &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 1, or febrile neutropenia or grade 4 neutropenia at any time during cycle, discontinue treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Thrombocytopenia:",
"        </strong>",
"        If day 1 treatment delayed for platelet count &lt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , reduce oxaliplatin dose to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and reduce the continuous infusion FU to 75 percent of original doses. For second occurrence, reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . If non-recovery after two weeks delay or third occurrence of platelets &lt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , discontinue treatment. For grade 3 or 4 thrombocytopenia",
"        <em>",
"         during",
"        </em>",
"        treatment, reduce oxaliplatin dose to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the infusional FU dose to 75 percent of the original dose. For the second occurrence, reduce dose of irinotecan to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the dose of infusional FU an additional 25 percent. Discontinue treatment for third occurrence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Do not retreat with FOLFOXIRI until resolution of diarrhea for at least 24 hours without anti-diarrheal medication. For diarrhea grade 3 or 4, or diarrhea with fever and/or grade 3 or 4 neutropenia, reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the continuous FU dose to 75 percent of original dose. For second occurrence, reduce the oxaliplatin dose to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and the dose of infusional FU an additional 25 percent. Discontinue treatment for third occurrence.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis or palmar-plantar erythrodysesthesia:",
"        </strong>",
"        For grade 3 to 4 toxicity, reduce dose of infusional FU by 25 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting more than seven days, decrease oxaliplatin dose by 25 percent",
"        <sup>",
"         [3]",
"        </sup>",
"        . Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        Any other toxicity &ge;grade 2, except anemia and alopecia, can justify dose reduction if medically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte colony stimulating factors; CBC: complete blood count.",
"     <br/>",
"     * A lower initial dose of irinotecan is recommended for patients &ge;65 years of age, poor performance status, or prior pelvic or abdominal radiotherapy. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Many centers routinely infuse oxaliplatin via central venous line because of local pain with infusion into a peripheral vein.",
"     <br/>",
"     &sect; Leucovorin dose is given for LEVOleucovorin (l-leucovorin, Fusilev)",
"     <sup>",
"      [7]",
"     </sup>",
"     . Double the dose if using the d,l-racemic mixture.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Falcone A, et al. J Clin Oncol 2007; 25:1670.",
"      </li>",
"      <li>",
"       Masi G, et al. Ann Oncol 2004; 15:1766.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin) injection. US FDA approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 16, 2011).",
"      </li>",
"      <li>",
"       Camptosar (irinotecan hydrochloride) injection. US FDA approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 16, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 28, 2011.",
"      </li>",
"      <li>",
"       Conroy T, et al. N Engl J Med 2011; 364:1817.",
"      </li>",
"      <li>",
"       Fusilev (levoleucovorin calcium) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 16, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_32_3599=[""].join("\n");
var outline_f3_32_3599=null;
